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Abstract 
Incidence rates for both melanoma and non-small cell lung cancer (NSCLC) have risen in 
recent decades. While advanced cases of both diseases have previously demonstrated low 
survivability, novel therapies such as immune checkpoint inhibitors, have significantly 
improved the outcome of patients suffering from these cancers. Recent clinical trials have led 
to the United States Food and Drug Administration (FDA) approving the use of antibodies 
targeting the PD-1 immune checkpoint for both melanoma and NSCLC. Anti-PD-1 antibodies 
have been seen to illicit responses in up to 40% of patients, however, particularly for 
melanoma, there is a lack of biomarkers to select for patients likely to respond.  
PD-L1 expression in tumour tissue is the most studied biomarker of response to anti-PD-1 
therapy in melanoma patients and is also the biomarker currently in use as a companion 
diagnostic test for NSCLC patients. It is believed that circulating tumour cells (CTCs) that break 
away from the tumour and enter the bloodstream, would share the same immune escape 
mechanisms as the parent tumour, and so would express PD-L1 in the same way as the 
tumour. Therefore, we postulate that these cells provide an accessible tumour sample for 
analysis of PD-L1 expression. 
A previous study by our group used multi-marker flow cytometry to evaluated PD-L1 
expression on CTCs from melanoma patients commencing anti-PD-L1 therapy. Here, the PD-
L1 expression on CTC from the latter study was compared to PD-L1 expression in matched 
tumour tissues. Moreover, this study describes the establishment of methodologies for 
immunocytochemistry analysis and scoring of PD-L1 expression on melanoma CTCs and on 
carcinomas CTCs, including NSCLC. Cell lines representing negative, low and high PD-L1 
expression were identified to serve as controls, again for both melanoma and carcinomas. To 
further evaluate our methods, CTCs were extracted from the blood samples of patients with 
melanoma and NSCLC using microfluidic devices and immunostained to investigate the 
expression of PD-L1. Finally, comparison between CTC and tumour tissue PD-L1 expression 
was carried out in a small number of cases. 
Overall, this study successfully developed immunocytochemistry protocols to effectively 
identify and score PD-L1 expression on both melanoma and carcinoma CTCs, thus providing 
a basis for further work to evaluate the clinical potential of CTCs. 
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1.1. Introduction 
Incidence rates for lung cancer and melanoma have increased substantially over the past 
several decades (Garbe and Leiter, 2009; Molina et al., 2008). Five-year survival rates for 
NSCLC are still less than 5% and until recently, it was common for metastatic melanoma to be 
fatal within 18 months (Garbe and Leiter, 2009; Molina et al., 2008). However, treatment 
options for both advanced NSCLC and metastatic melanoma have improved dramatically with 
the advent of novel therapies, including checkpoint inhibitors such as anti-PD-1 antibodies 
(Luke et al., 2017; Somasundaram et al., 2016). 
Anti-PD-1 antibodies have been extensively studied in clinical trials to determine their efficacy 
(Brahmer et al., 2010; Luke et al., 2017; Somasundaram et al., 2016; Topalian et al., 2012). 
Though these antibodies have been demonstrated to have high response rates, they also have 
significant side effects (Larkin et al., 2015). This, combined with the high cost of treatment, 
has led to attempts to find biomarkers of response to treatment (Jessurun et al., 2017). The 
only biomarker currently in clinical use to determine the suitability of treatment with anti-PD-
1 therapy is the evaluation by IHC of PD-L1 expression in NSCLC tumour tissue. The IHC 
analysis of PD-L1 expression in this  was is used to qualify patients for first line therapy with 
pembrolizumab (Teixido et al., 2018). 
Circulating tumour cells (CTCs) are capable of expressing the same immune escape 
mechanisms as the tumour that they arose from (Aya-Bonilla et al., 2019). Though there has 
been a significant increase in PD-L1 assessment on NSCLC CTCs in recent years, these results 
are not conclusive and there have been a limited number of comparisons to expression in 
tumour tissue (Adams et al., 2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et al., 2017). 
Meanwhile, there has only been a single study assessing PD-L1 expression on melanoma CTCs 
relative to treatment response and comparing it to expression in tumour tissue (Khattak et 
al., 2019). It may therefore be possible to use CTC expression of PD-L1 from a liquid biopsy as 
a predictive biomarker of response to therapy or as a replacement companion diagnostic test 
for tumour tissue expression. 
 
   
1.2. Immune checkpoint blockade: Anti-PD-1 therapies 
1.2.1. Immune checkpoint molecules 
Immune checkpoint molecules regulate the immune system to maintain self-tolerance and 
control the duration and level of immune response (Pardoll, 2012). There are several known 
immune checkpoint molecules, which can be categorised into two primary groups, 
stimulatory and inhibitory checkpoint molecules. Of the inhibitory checkpoint molecules 
there are currently 11 known, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM-
3 and VISTA (some of which are included in Figure 1) (Dangaj et al., 2013; Derre et al., 2010; 
Huang et al., 2004; Kolar et al., 2009; Leitner et al., 2009; Leone et al., 2015; Lines et al., 
2014; Prendergast et al., 2014; Topalian et al., 2012; Zhu et al., 2011). Inhibitory immune 
checkpoint molecules are integral in the functioning of the healthy immune system and 
have recently been of particular interest due their involvement in cancer immune escape. 
As a result, a variety of therapeutic agents have been developed and studied to block or 
reactivate their signalling to promote immune cell activation (Pardoll, 2012; Postow et al., 
2015; Wei et al., 2018). 
 
 
Figure 1. Depiction of various ligand-receptor interactions between T cells and antigen-presenting 
cells that regulate T cell responses, including multiple immune checkpoint molecules (Pardoll, 2012). 
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1.2.2. Mechanism of PD-1 signalling 
Of the 11 known inhibitory immune checkpoint molecules, this study will focus on PD-1/PD-
L1 axis given its demonstrated clinical relevance for the treatment of cancer (Le et al., 2015; 
Motzer et al., 2015; Nghiem et al., 2016; Powles et al., 2014; Topalian et al., 2012) . PD-1 
was first discovered to be an inhibitory immune checkpoint molecule in 1999, though its 
means of action were not known (Nishimura et al., 1999). It was later found that PD-L1, also 
known as B7-H1, was a ligand for PD-1 (Freeman et al., 2000). The binding and interaction 
between PD-1 and PD-L1 has been identified as a normal part of immune regulation that 
protects native tissue from autoimmune damage (Barber et al., 2006; Freeman et al., 2000). 
PD-1 is expressed on T cells, B cells and myeloid cells and high levels of expression, 
compared to other CD28 molecules, suggests that PD-1 regulates a wide range of immune 
responses (Liang et al., 2003; Okazaki and Honjo, 2007).  
PD-1 has two ligands, PD-L1 and PD-L2; both are transmembrane glycoproteins that interact 
with PD-1 to affect the immune system through subsequent PD-1 signalling as neither PD-
L1 or PD-L2 possess a means of signal transduction (Okazaki and Honjo, 2007). PD-L1 and 
PD-L2 can be found in a plethora of different tissues including lymphoid, heart and lung 
tissues (Liang et al., 2003). As PD-L1 is expressed in both lymphoid and non-lymphoid 
tissues, it is believed that interaction between PD-1 and PD-L1 could regulate immune 
responses in both secondary lymphoid organs and target organs (Okazaki and Honjo, 2007). 
Recent findings by Zhao et al. in 2019 demonstrated that presence of PD-L1 can also reduce 
cell surface expression of CD80, the ligand for cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), on antigen-presenting cells. This interaction allows PD-L1 to exert 
immunostimulatory effects through the repression of the CTLA-4 immune checkpoint (Zhao 
et al., 2019). 
Interaction between PD-1 and PD-L1 suppresses aberrant immune responses that damage 
host tissue. However, despite PD-1 signalling, some normal healthy responses produced by 
the immune system are not affected, such as that required for effective anti-bacterial 
immune responses (Okazaki and Honjo, 2007). 
Stimulation of T cell receptors activates the phosphatidylinositol 3-kinase (PI3K) signalling 
cascade (Parry et al., 2005). This cascade involves the activation of the Akt pathway, which 
is responsible for mediating the cell growth and proliferation of T cells as well as cytokine 
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production, among other effects (Manning and Cantley, 2007). The binding of PD-L1 to PD-
1 receptors on activated effector T cells results in a signal to attract phosphatase SHP-2, 
which can lead to the inactivation of the PI3K signalling cascade (Figure 2) (Chemnitz et al., 
2004; Parry et al., 2005). Akt deactivation, as a downstream result of PD-1 signalling, has 
been established as a casual mediator of cell death and thus reduces both T cell levels and 
activation (Luo et al., 2003; Parry et al., 2005). The gross result of these events, initiated by 
PD-1 signalling, is the inhibition of T cell activation and proliferation, blockage of cytokine 
production and general obstruction of immune processes that would otherwise lead to the 
destruction the target cell (Chen and Mellman, 2013). 
 
Figure 2. PD-1 signalling. Ligation of T-cell receptor and PD-1 leads to tyrosine phosphorylation (P) 
of the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based 
switch motif (ITSM) of PD-1. Binding of the ITSM by SHP-1 or SHP-2 results in the dephosphorylation 
of proximal signalling molecules and augmentation of PTEN expression. This effectively attenuates 
the activation of the PI3K and Akt pathways. PD-1 signalling may result in decreased T-cell 
proliferation, survival, protein synthesis and IL-2 production. (Red arrows and text indicate 
consequence of PD-1 mediated signalling) Adapted from (Francisco et al., 2010).  
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PD-1 stimulation produces a signal that is vital for the regulation of the immune system by 
host cells, however, genetic mutations can affect this function. Over thirty different single 
nucleotide polymorphisms have been identified in the human PDCD1 gene (which encodes 
the PD-1 protein) (Okazaki and Honjo, 2007). These single nucleotide polymorphisms in the 
human PDCD1 gene have been associated with a variety of diseases including systemic lupus 
erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, ankylosing 
spondylitis, myocardial infarction and allergies (Bennet et al., 2006; James et al., 2005; 
Kroner et al., 2005; Lee et al., 2006; Nielsen et al., 2003; Prokunina et al., 2002; Prokunina 
et al., 2004). These studies demonstrate the importance of the PD-1 immune checkpoint 
and why some of these ailments are seen as immune related adverse events when anti-PD-
1 therapy is administered (Bennet et al., 2006; James et al., 2005; Kroner et al., 2005; Lee 
et al., 2006; Nielsen et al., 2003; Prokunina et al., 2002; Prokunina et al., 2004). 
1.2.3. Immune checkpoint activation and tumour immune escape 
In 2002, PD-L1 was found to be expressed on the surface of several tumours (Dong et al., 
2002) . Knowledge of the function of PD-1 signalling in healthy tissues led to the suggestion 
that PD-L1 expression on these tumours bolstered their ability to evade the immune system 
(Dong et al., 2002). There are two primary hypotheses as to how tumours initially begin 
expressing PD-L1; innate response and adaptive response. The innate response hypothesis 
suggests that tumours begin to express PD-L1 as a side effect of other signalling happening 
in the cells (Pardoll, 2012). In contrast, the second hypothesis of adaptive response suggests 
that cancer cells express PD-L1 as a protective mechanism after invasion by lymphocytes 
allowing tumour growth (Taube et al., 2012). This immune control is antigen specific 
blocking anti-cancer T cells while the host’s immune system continues to function correctly 
for any other antigens (Ribas, 2015a).  This mechanism was first used to describe how the 
production of interferons by T cells upon recognition of their cognate antigen results in the 
reactive expression of the ligand of PD-1 (PD-L1) by cancer cells and the inactivation of PD-
1 expressing T cells (Pardoll, 2012). Secretion of interferon-γ (IFN-γ) by cytotoxic T 
lymphocytes is known to up-regulate PD-L1 expression in tumour cells from mouse models 
of various cancer types (Abiko et al., 2015; Blank et al., 2004). This interaction has also been 
observed in cell lines derived from human tumours, confirming that IFN-γ induces PD-L1 up-
regulation in human cancers (Chen et al., 2012; Gao et al., 2018; Gowrishankar et al., 2015). 
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1.2.4. Immune checkpoint inhibitors 
Antibodies targeting immune checkpoint molecules can serve as a means to alter the cell 
mediated immune response, primarily to enable the targeting of cancerous cells. They 
function by binding to immune checkpoint molecules or receptors so as to inhibit signalling 
that would otherwise prevent T cell activation and response. T cell activation allows 
proliferation, increase cytokine production and other immune processes that lead to the 
destruction the target cell (Chen and Mellman, 2013).  
Anti-PD-1 therapies target and bind to PD-1 receptors, effectively blocking the receptor 
from binding to either of its ligands, thus preventing immune suppression (Figure 3) (Chen 
and Mellman, 2013). To date, PD-1/PD-L1 inhibitors have been approved for the treatment 
of a variety of cancers including melanoma, NSCLC, renal cell carcinoma, bladder cancer, 
colorectal cancer and squamous cell carcinoma of the head and neck, among some others 
(Diaz et al., 2017; Le et al., 2015; Motzer et al., 2015; Nghiem et al., 2016; Powles et al., 
2014; Topalian et al., 2012). Approved treatments nivolumab and pembrolizumab are both 
monoclonal antibodies that function in essentially the same way by binding to the PD-1 
receptor and disabling its interaction with PD-L1 (Postow et al., 2015). Anti-PD-L1 
antibodies, such as atezolizumab, block the same pathway as anti-PD-1 antibodies but exert 
slightly different effects (Butte et al., 2007). PD-L1 does not only interact with the PD-1 
receptor, the molecule also interacts with B7-1 as a secondary means to exert negative 
signals on T cells (Butte et al., 2007). PD-L1 antibodies also differ from PD-1 antibodies in 
that they do not inhibit the interaction of PD-1 and PD-L2. However, the importance of this 
interaction in relation to T cell activity is relatively unknown (Postow et al., 2015). 
 
Figure 3. T cell activation in the tumour microenvironment. a. PD-1 and PD-L1 interaction activate 
signalling to inhibit T cell activity, blocking anti-tumour responses. b. Antibodies targeting either PD-
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1 or PD-L1 block the interaction and allow T cell activation, producing an anti-tumour response 
(Farkona et al., 2016; Ribas, 2015b). 
1.3. Currently approved anti-PD-1 therapies 
Several large, randomised, phase III studies conducted on advanced-stage melanoma 
patients that have been completed in recent years demonstrated therapeutic outcomes in 
patients treated with anti-PD-1 antibodies (Figure 4). The success of these studies led to the 
approval of anti-PD-1 antibodies, alone and in combination with anti-CTLA4, by the United 
States Food and Drug Administration (FDA) for treating melanoma (Hodi et al., 2015; Luke 
et al., 2017). There are currently two anti-PD-1 antibodies approved for single use in 
melanoma patients, nivolumab and pembrolizumab (Postow et al., 2015). 
Nivolumab was first approved for the treatment of advanced melanoma in 2014, based on 
the results of CheckMate 066. CheckMate 066 was a phase 3 clinical trial which compared 
nivolumab to dacarbazine in untreated, unresectable or metastatic melanoma (Robert et 
al., 2015b). Patents participating in CheckMate 066 were treated with either nivolumab or 
dacarbazine until disease progression or unacceptable toxicity. At the latest report, a 
minimum follow-up of 38.4 months for the nivolumab group provided a median overall 
survival (OS) of 37.5 months, while a minimum follow-up of 38.5 months for the dacarbazine 
group provided a median OS of 11.2 months. The three year OS rate for nivolumab was also 
considerably higher than that for dacarbazine, being 51.2% and 21.6% respectively (Ascierto 
et al., 2019). The median progression free survival (PFS) for the nivolumab and dacarbazine 
groups were 5.1 months and 2.2 months respectively. Much like OS and PFS, the response 
rates for the nivolumab group were considerably higher than those for the dacarbazine 
group. The objective response rate (ORR) for the nivolumab group was 42.9%, with a 
median duration of response not being reached (38.2-NR). Conversely, the ORR for the 
dacarbazine group was 14.4%, with a median duration of response being 6 months (3.9-
24.3 months) (Ascierto et al., 2019). All of the results from CheckMate 066 conclusively 
demonstrated the superiority of nivolumab to dacarbazine in untreated, unresectable or 
metastatic melanoma. Since this first FDA approval, nivolumab has been approved in 
combination with ipilimumab for treating advanced melanoma (CheckMate 069) (Hodi et 
al., 2015) and alone as an adjuvant therapy in patients with completely resected melanoma 
with lymph node involvement or metastatic disease (CheckMate 238) (Weber et al., 2017). 
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Pembrolizumab was also first approved for the treatment of advanced melanoma in 2014, 
based on the results of KEYNOTE-002. KEYNOTE-002 was a phase 2 clinical trial which 
compared pembrolizumab to chemotherapy in patients with advanced melanoma (Ribas et 
al., 2015). Patients participating in KEYNOTE-002 were randomly assigned to three groups 
to be treated with either pembrolizumab 2 mg/kg or 10mg/kg every 3 weeks or investigator-
choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or 
oral temozolomide) until disease progression or unacceptable toxicity. The 9-month PFS 
was 24% and 29% for the pembrolizumab 2 mg/kg or 10mg/kg respectively, and 8% for the 
investigator-choice chemotherapy (Ribas et al., 2015). However, pembrolizumab treatment 
did not provide a statistically significant improvement in the median OS when compared to 
chemotherapy. The median OS for the pembrolizumab 2 mg/kg or 10mg/kg groups was 13.4 
(11.0-16.4) and 14.7 months (11.3-19.3) respectively, versus 11.0 months (8.9-13.8) for the 
chemotherapy group. Finally, the ORR for both pembrolizumab 2 mg/kg and 10mg/kg was 
significantly higher than for chemotherapy, being 22%, 28% and 4% respectively (Hamid et 
al., 2017). The results of KEYNOTE-002 demonstrated the significant improvements in PFS 
for advanced melanoma patients when treated with pembrolizumab versus treatment with 
chemotherapy. Since this first FDA approval of pembrolizumab for the treatment of 
melanoma, it has received an expanded indication for treating advanced melanoma 
patients, now being available as a first line treatment. This expanded indication for 
pembrolizumab was approved based on the results of KEYNOTE-006 (Schachter et al., 2017). 
FDA approval for pembrolizumab was also further expanded to include adjuvant treatment 
of melanoma patients with involvement of lymph nodes following complete resection due 
to the results from KEYNOTE-054 (Eggermont et al., 2018). 
For NSCLC, much like in melanoma, immune checkpoint blockade has been shown as an 
effective treatment. Since 2010 there have been a number of anti-PD-1 studies involving or 
focusing on NSCLC patients (Figure 4) (Somasundaram et al., 2016). These studies resulted 
in the approval of PD-1 checkpoint blockade antibodies nivolumab and pembrolizumab to 
treat NSCLC.  
Nivolumab was first approved for the treatment of NSCLC in 2015 based on the results from 
CheckMate 017. CheckMate 017 was a phase 3 clinical trial which compared nivolumab to 
docetaxel in patients with previously treated advanced or metastatic squamous NSCLC 
(Brahmer et al., 2015). Patients participating in CheckMate 017 were treated with either 
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nivolumab or docetaxel until progression or unacceptable toxicity. The study reported a 
minimum follow up of 11 months, with a median OS of 9.2 months in the nivolumab group 
and 6 months in the docetaxel group. The OS for the nivolumab group was significantly 
higher after one year, being 42% versus the 24% OS for the docetaxel group. Median PFS 
was also higher for the nivolumab group, being 3.5 months compared to 2.8 months for the 
docetaxel group. The ORR was significantly higher for the nivolumab group, with 20% of 
patients responding compared to the 9% response rate for the docetaxel group. Finally, the 
median duration of response was not reached for the nivolumab group, being 2.9 to 20.5+ 
months, compared to the significantly shorter 8.4 month median for the docetaxel group 
(1.4 to 15.2+) (Brahmer et al., 2015). Following this first approval of nivolumab for the 
treatment of NSCLC, the FDA expanded the approval to include non-squamous NSCLC based 
on the results from CheckMate 057 (Borghaei et al., 2015). 
Pembrolizumab was first approved for the treatment of NSCLC in 2015 based on the results 
from KEYNOTE-001 and KEYNOTE-010. KEYNOTE-001 was a phase 1 clinical trial assessing 
pembrolizumab in patients with locally advanced or metastatic carcinoma, melanoma or 
NSCLC (Robert et al., 2014). KEYNOTE-010 was a phase 2 clinical trial comparing 
pembrolizumab to docetaxel in previously treated participants with NSCLC (Herbst et al., 
2016). Patients participating in KEYNOTE-010 were randomly assigned to one of three 
groups to be treated with either pembrolizumab 2 mg/kg or 10mg/kg every 3 weeks or 
docetaxel, until disease progression or unacceptable toxicity. The median OS for the 
pembrolizumab 2 mg/kg or 10mg/kg groups was higher than for the docetaxel group, being 
10.4 (9.4 – 11.9), 12.7 (10.0 – 17.3) and 8.5 months (7.5 – 9.8) respectively. PFS was not 
significantly different between docetaxel and either the pembrolizumab 2 mg/kg or 
10mg/kg groups for the total patient population. The ORR for patients treated with 
pembrolizumab was double that of those treated with docetaxel, being 18% for both dosage 
groups compared to 9% for the docetaxel group. Patients participating in KEYNOTE-010 also 
had tumour tissue assessed for PD-L1 expression using the 22C3 pharmDx 
immunohistochemistry assay. Patients were split into two sub-groups for further 
assessment, those with PD-L1 expression in at least 50% of tumour cells vs those with less 
than 50% of tumour cells expressing PD-L1. When performing the same analyses for the ≥ 
50% tumour PD-L1 group as were done for the total population, there were larger 
differences in OS, PFS and ORR between the pembrolizumab treated groups and the 
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docetaxel group. These results demonstrated that response to pembrolizumab was 
improved for patients with ≥ 50% of tumour cells expressing PD-L1 (Herbst et al., 2016). 
Since the first approval of pembrolizumab for the treatment of NSCLC, there have been 
multiple expansions of the approved treatment. These include expansions in approval as a 
first line treatment based on the results of KEYNOTE-24 (Reck et al., 2016) and KEYNOTE-
042 (Mok et al., 2019). Pembrolizumab has also been approved in combination with 
pemetrexed and carboplatin, pemetrexed and platinum chemotherapy or carboplatin and 
either paclitaxel/nab-paclitaxel based on the results of KEYNOTE-021 (Langer et al., 2016), 
KEYNOTE-189 (Sheela et al., 2018) and KEYNOTE-407 (Paz-Ares et al., 2018) respectively.
   
 
Figure 4. Timeline charting the seminal, practice-changing clinical trials of anti-PD-1 antibodies in advanced-stage melanoma (top) and NSCLC (bottom). 
   
 
There have also been a number of clinical trials involving melanoma and NSCLC patients 
assessing anti-PD-L1 antibodies. Several early clinical trials using anti-PD-L1 antibodies, such 
as NCT01375842, which evaluated safety, tolerability and pharmacokinetics of 
atezolizumab in participants with locally advanced or metastatic solid tumours, 
demonstrated the efficacy of atezolizumab (Herbst et al., 2014). NCT01375842 
demonstrated that atezolizumab produced an ORR of 26 % in melanoma patients and 21% 
in NSCLC patients (Herbst et al., 2014). Based on the following OAK trial, atezolizumab was 
approved as a treatment for multiple cancers, including NSCLC provided other treatment 
options have previously failed (Rittmeyer et al., 2017). 
Other anti-PD-L1 antibodies have reached clinical development in recent years, including 
the monoclonal antibody MDX-11-5 which was shown to be capable of producing durable 
responses in a variety of cancers (Brahmer et al., 2012). The phase 1 clinical trial 
NCT00729664 demonstrated that MDX-11-5 had an ORR of 17% with a 24-week PFS of 42% 
for melanoma patients, while NSCLC patients had an ORR of 10% with a 24 week PFS of 31% 
(Brahmer et al., 2012). There are, however, no anti-PD-L1 antibodies that have been 
approved for the treatment of melanoma (Postow et al., 2015). 
1.3.1. Side effects 
Coinciding with their potential to cause tumour regression, immune checkpoint inhibitors 
may also lead to a multitude of adverse effects, including autoimmune responses (Eigentler 
et al., 2016; Phan et al., 2003). Immune checkpoint inhibitors are distinctly different in the 
type of toxicity that they produce when compared to cytotoxic or targeted agents (Robert 
et al., 2011). Immune related adverse events are the main form of toxicity for immune 
checkpoint inhibitors several cancer types, with up to 90% of anti-CTLA-4 treated patients, 
and up to 70% of anti-PD-1 treated patients being affected by adverse events (Hodi et al., 
2010; Topalian et al., 2012). Immune related adverse events are graded on a scale of one to 
five using the Common Terminology Criteria for Adverse Events, with grades one through 
five being classified as mild, moderate, severe, life threatening and death related to toxicity 
respectively (Institute, 2009). Skin manifestations are the most common adverse effects 
related to CTLA-4, PD-1 and PD-L1 immune checkpoint blockade in melanoma patients 
(Figure 5); histological analysis of  skin from adversely affected patients often shows deep 
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perivascular lymphocytic infiltration in the dermis with CD4+ and CD8+ cells in close 
proximity to melanocytes (Jaber et al., 2006). 
 
Figure 5. Distribution of grade I-II and grade III-V immune related adverse events for all tumour types 
in the main clinical trials using anti-CTLA-4, anti-PD-1 or anti-PD-L1 as single therapies. Bar graphs 
depict the percent of patients experiencing adverse events with values quoted for the median 
(range). Adapted from (Michot et al., 2016). 
The most common adverse effects associated with anti-PD-1 treatment include diarrhoea, 
rash, pruritus and fatigue (Michot et al., 2016; Robert et al., 2015b). Other, less common 
but potentially more serious, adverse effects that can be produced by immune responses 
associated with anti-PD-1 therapy include, but are not limited to, hypothyroidism, 
hyperthyroidism and colitis (Robert et al., 2015b). Severe or prolonged treatment-related 
adverse effects result in discontinuation of treatment with anti-PD-1 antibodies despite 
active response in four to twenty-five percent of patients depending on the treatment 
regime (Robert et al., 2017; Robert et al., 2015b).   
While the combination of anti-PD-1 and anti-CTLA-4 therapies has a higher objective 
response rate than either alone as a monotherapy in melanoma patients, the incidence of 
high grade immune related adverse events also increases (Figure 6). In the Checkmate 067 
phase III clinical trial the majority of patients experienced some level of treatment related 
adverse event, with 82.1%, 86.2% and 95.5% of patients affected from the nivolumab, 
ipilimumab and nivolumab + ipilimumab groups respectively (Larkin et al., 2015). The 
number of grade 3 or 4 treatment related adverse events was also raised, effecting 55% of 
the nivolumab + ipilimumab group compared to 16.3% and 27.3% of the nivolumab and 
ipilimumab groups respectively. Finally, cessation of treatment due to severe treatment 
related adverse events occurred in 7.7%, 14.8% and 36.4% of patients from the nivolumab, 
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ipilimumab and nivolumab + ipilimumab groups respectively (Larkin et al., 2015). These 
results show that combination therapy increases the severity of immune related adverse 
events for all tumour types. 
 
Figure 6. Treatment related adverse events associated with nivolumab, nivolumab plus ipilimumab 
and ipilimumab treatments in melanoma patients, adapted from (Larkin et al., 2015). 
Much like other immune checkpoint inhibitors, treatment related adverse events are 
experienced by a number of patients undergoing anti-PD-L1 therapy. The OAK clinical trial 
that led to the approval of Atezolizumab for treatment of NSCLC patients, among others, 
reported that 64% of patients (390 of 609) experienced treatment related adverse events. 
Far fewer patients, 15% (90 of 609), experienced grade 3-4 treatment related adverse 
events (Rittmeyer et al., 2017). 
1.4. Biomarkers of response to anti-PD-1 therapy 
1.4.1. Biomarkers in research 
As stated above, immune checkpoint inhibitors have rapidly become a key treatment option 
in advanced stage melanoma and NSCLC patients. Anti-PD-1 therapy in particular has shown 
significant promise, affecting a durable response in 26% - 40% of patients (Ribas et al., 2016; 
Robert et al., 2015a; Robert et al., 2015b; Topalian et al., 2014). However, toxicities and 
adverse events associated with the treatment, combined with the response rate, have 
resulted in the search for a biomarker to identify responders prior to or early during 
treatment. 
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The identification of potential biomarkers in melanoma patients has seen moderate success 
when assessing tumour tissue through a variety of means. A slew of studies have displayed 
varying degrees of correlation between response and potential biomarkers including high 
mutational load (Hugo et al., 2016), high neoantigen load (McGranahan et al., 2016), 
immune gene expression signature (Hugo et al., 2016) and high levels of CD8+ T cell infiltrate 
(Weber et al., 2013) among others (Figure 7). Circulating proteins demonstrating diagnostic 
and prognostic value include S100B, C reactive protein and melanoma-inhibiting activity 
protein (Vereecken et al., 2012). Blood-based biomarkers showing correlation with 
response to anti-PD-1 therapy include T cell receptor diversity (Tumeh et al., 2014), Bim-
expressing T cells (Dronca et al., 2016) and plasma soluble PD-L1 (Zhou et al., 2017). PD-L1 
expression in tumour tissue is currently the most studied potential biomarker, and also the 
most predictive biomarker, of response to anti-PD-1 therapy in advanced stage melanoma 
(Jessurun et al., 2017). 
 
Figure 7. Biomarkers of response to PD-1 immune checkpoint inhibitor (ICI) in melanoma tumour 
tissue. Graphs show the number of studies reported per biomarker type for correlations with clinical 
response, progression-free survival (PFS), or overall survival (OS) upon PD-1 ICI therapy. Black bars 
indicate significant correlation, white bars indicate non-significant correlation. Adapted from 
Jessurun et al 2017 (Jessurun et al., 2017). 
For NSCLC, unlike melanoma, there are multiple other treatment options that may offer 
prolonged clinical benefit (Carmichael et al., 2018). Other potential first line treatments that 
are often considered for treating NSCLC include chemotherapy (Schiller et al., 2002), 
epidermal growth factor receptor blockers (Shepherd et al., 2005), vascular endothelial 
growth factor inhibitors (Reck et al., 2009) and ALK blockers (Camidge et al., 2012). 
Therefore, it is critical to choose therapies to which the patient is likely to respond. This has 
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led to a significant number of studies assessing potential biomarkers of response to anti-
PD-1 treatment to enable identification of NSCLC responders that can receive anti-PD-1 as 
a first-line treatment. The potential biomarkers being studied in NSCLC include antigen-
specific T cells (Dhodapkar et al., 2013), the mutational load of the tumour (Rizvi et al., 2015) 
and loss of mutation-associated neoantigens (Anagnostou et al., 2017). However, PD-L1 
expression in tumour tissue is the only biomarker for response to anti-PD-1 therapy that 
has been approved by the FDA as a companion or diagnostic test to decide treatment with 
pembrolizumab as first line therapy (Teixido et al., 2018). 
1.4.2. PD-L1 as a biomarker 
The first evidence suggesting the potential of PD-L1 as a predictive biomarker of response 
to anti-PD-1 therapy was produced by the first human phase I nivolumab trial, conducted in 
patients with varying solid tumour types. The results of this study showed that patients with 
PD-L1 expression at the cell surface were likely to respond to anti-PD-1 therapy whereas all 
patients that were not positive for PD-L1 expression at the cell surface failed to respond to 
treatment (Brahmer et al., 2010). However, the sample size of the study was small, a total 
of 9 biopsies were tested for PD-L1 expression, and so this result would require further 
research before it could be validated. Several subsequent trials have assessed PD-L1 
expression in tumour biopsies, producing similar results and supporting the potential of PD-
L1 as a predictive biomarker. However, none of these follow up clinical trials have managed 
to demonstrate a response rate as high as the initial trial. One of these follow up clinical 
trials was the phase I study of nivolumab in subjects with advanced or recurrent 
malignancies, which demonstrated that PD-L1 expression in tumour biopsies correlated 
with clinical benefit to the anti-PD-1 therapy but did not significantly correlate with 
objective response (Topalian et al., 2012).  
Several other studies assessing PD-L1 expression in the tumour tissue of melanoma patients 
have linked expression to treatment response. However, these studies have been 
inconsistent in demonstrating a significant correlation between expression and treatment 
response (Daud et al., 2016; Kaunitz et al., 2017; Topalian et al., 2012). A study of 
pembrolizumab in participants with progressive locally advanced or metastatic carcinoma, 
melanoma, or NSCLC also demonstrated that melanoma patients with higher levels of PD-
L1 expression were more likely to respond to treatment. PD-L1 expression was scored on a 
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0-5 scale by the percentage of cells staining positive, 0 being 0% and 5 being ≥ 66% (Figure 
8).  Objective response rates to pembrolizumab were calculated individually for each group 
as 8%, 12%, 21%, 40%, 57% and 50%, for patients with scores 0-5 respectively (Daud et al., 
2016). 
 
Figure 8. Photomicrographs depicting immunohistochemical staining of PD-L1 (22C3 antibody) in 
melanoma (MEL) samples. PD-L1 staining seen as brown chromogen, whereas blue is haematoxylin 
counterstain (Daud et al., 2016). 
PD-L1 expression is highly variable between separate melanoma subtypes, whilst following 
a general trend within the subtypes. This has been demonstrated by a study using 
immunocytochemistry to stain for PD-L1 in patients with rare melanoma subtypes. This 
study found that PD-L1 is more highly expressed in chronic sun damaged melanomas such 
as lentigo maligna, which has a higher response rate to anti-PD-1 therapy, and has lower 
expression in uveal melanoma, which has lower response rate to anti-PD-1 therapy, when 
comparing each to cutaneous melanoma (Kaunitz et al., 2017). The tumour mutational 
burden (TMB) of each of these melanoma subtypes also parallels the PD-L1 expression and 
response rate to anti-PD-1 therapy, with chronic sun damage melanomas having the highest 
TMB and uveal having the lowest (Kaunitz et al., 2017). This study is significant as the results 
provide a potential factor contributing to the different objective response rates for each 
melanoma subtype. The general conclusion reached by these studies is that PD-L1 
expression in tumour tissue does correlate with response rate, with the caveat that it is still 
possible for some PD-L1 negative patients to respond to treatment (Daud et al., 2016; 
Powles et al., 2014; Topalian et al., 2012).  
PD-L1 expression in NSCLC tumour tissue has been studied extensively to determine its 
potential as a biomarker for anti-PD-1 therapies. Although PD-L1 expression in tumour 
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tissue was integral to the approval of pembrolizumab as a first line treatment for NSCLC, 
15% of PD-L1 negative patients achieve an objective response to treatment (Garon et al., 
2015). Nonetheless, pembrolizumab is only approved by the FDA and Australian 
Therapeutic Goods Administration as a first line treatment in EGFR and ALK negative 
patients given a positive result from a companion diagnostic test assessing PD-L1 
expression, specifically staining with the 22C3 pharmDx assay (Teixido et al., 2018). A 
positive result from the 22C3 pharmDx assay was previously listed as a tumour proportion 
score of ≥ 50% (Pai-Scherf et al., 2017), with this tumour proportion score being  observed 
in 35% of patients (Garon et al., 2015). The 22C3 monoclonal antibody was approved as the 
companion diagnostic test for pembrolizumab due to the results of two large phase III 
clinical trials, KEYNOTE-010 and KEYNOTE-024 (Herbst et al., 2016; Reck et al., 2016). 
KEYNOTE-010 and KEYNOTE-024 studied responses to pembrolizumab in PD-L1 positive 
patients, based on the 22C3 pharmDx assay, as a first line treatment (KEYNOTE-024) and a 
second line treatment (KEYNOTE-010). Both clinical trials found that pembrolizumab 
prolonged overall survival with minimal risk, establishing the antibody as a suitable new 
treatment option (Herbst et al., 2016; Reck et al., 2016). However, since then, a positive 
result from the 22C3 pharmDx assay has been adjusted to ≥ 1% based on the results from 
KEYNOTE-042 (Lopes et al., 2018). KEYNOTE-042 was an open-label phase 3 study 
comparing pembrolizumab versus platinum-based chemotherapy as first-line therapy for 
advanced/metastatic NSCLC with a PD-L1 tumour proportion score (TPS) ≥ 1%. The results 
of KEYNOTE-042 demonstrated that pembrolizumab provided higher overall survival than 
platinum-based chemotherapy for all patients with a TPS ≥ 1% (Lopes et al., 2018). 
The FDA has also approved 28.8 pharmDx as a diagnostic test for PD-L1 expression, for 
treatment with nivolumab as a second line therapy following platinum-based 
chemotherapy of NSCLC, although it has been listed as a nonessential complementary 
diagnostic test (Kazandjian et al., 2016). The Checkmate 057 clinical trial that led to the 
approval of nivolumab as a second line therapy found that PD-L1 expression, as determined 
by 28-8 pharmDx, was an appropriate biomarker (Kazandjian et al., 2016). The approval and 
utilisation of PD-L1 assays as diagnostic tests by the FDA demonstrates that PD-L1 
expression in tumour tissue is a directly relevant biomarker for anti-PD-1 therapy in NSCLC.  
1.5. Circulating tumour cells 
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CTCs were first observed and described in 1869 by Australian clinician Thomas Ashworth 
(Ashworth, 1869). Since then, a multitude of clinical studies involving CTCs have been 
conducted thanks to advances in the detection and isolation of the cells in more recent 
years (Adams et al., 2017; Alix-Panabieres and Pantel, 2014; Dhar et al., 2018; Guibert et al., 
2018; Ilié et al., 2017; Joosse et al., 2015; Krebs et al., 2010). CTCs are found in miniscule 
concentrations in the blood, there generally being between 1 – 10 cells in 10mL of blood, 
but this can be cancer-type dependant (Alix-Panabieres and Pantel, 2014). CTCs are thought 
to arise by detaching of cancer cells from the tumour mass and entering the blood stream. 
CTCs can leave the bloodstream and enter organs or tissues, leading to the development of 
new metastatic tumours (Figure 9) (Friedl and Alexander, 2011; Nguyen et al., 2009). Not 
all CTCs develop into metastases, a significant number are destroyed by the immune system 
or fail to survive without interaction with the extracellular and surrounding cellular matrix 
(Cohen et al., 2008). It is also unclear what proportion of CTCs have the capacity to seed 
new tumours (metastatic potential) based on whether they display cancer stem cell 
properties (Krebs et al., 2010). 
 
Figure 9. CTC extravasation and intravasation of blood vessels to form a metastasis (Cotran, 1991). 
1.5.1. CTC detection and enrichment techniques 
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The incredibly low number of CTCs, when compared to other blood cells, poses a significant 
challenge when trying to isolate them from the blood. Techniques to isolate CTCs therefore 
must be capable of differentiating them from other haematogenous cells. Isolation is 
achieved by utilising techniques that identify the differences between CTCs and 
haematogenous cells, such as physical or biological properties exhibited by the cells (Joosse 
et al., 2015). The primary biological property utilised for CTC isolation is the expression of 
proteins on the cell surface. In contrast, there are several physical properties that may be 
used to isolate CTCs including but not limited to cell size, cell density and the electric charge 
of the cell (Yu et al., 2011). Therefore, there are two general methods used for the isolation 
of CTCs, label-dependent methods and label-free methods (Joosse et al., 2015; Marsavela 
et al., 2018).  
Label dependent methods isolate CTCs from the blood by using antibodies that target 
tumour-associated antigens or common leukocyte antigens such as CD45. Immunomagnetic 
systems target unique CTC cell surface antigens with antibodies bound to magnetic beads. 
The beads, along with the attached cell, can then be isolated by exposing the mixture to a 
magnetic field (Alix-Panabieres and Pantel, 2014). An example of this type of system is the 
FDA approved CellSearch system, which utilises magnetic beads that target epithelial cell 
adhesion molecule (EpCAM) to isolate CTCs from epithelial tumours such as NSCLC (Pantel 
et al., 2009). There are a variety of CTC isolation systems that target EpCAM, including CTC-
chip (Sequist et al., 2009), herringbone-chip (Stott et al., 2010) and MagSweeper (Talasaz et 
al., 2009). All of these systems utilise EpCAM to target and isolate CTCs but use different 
means to do so (Alix-Panabieres and Pantel, 2014). 
Whilst EpCAM targeting systems are suitable for a variety of carcinomas such as NSCLC, they 
are not effective for the isolation of CTCs for non-epithelial cancers like melanoma. Label-
dependent melanoma CTC isolation therefore requires the use different cell surface 
markers, or the use of negative selection techniques. There has been difficulty in 
determining the best markers for the isolation of melanoma CTCs due to their heterogeneity 
(Gray et al., 2015). There are several markers that have been used individually to isolate 
melanoma CTCs including MCSP, MCAM, ABCB5 and CD271 (Freeman et al., 2012; Gray et 
al., 2015; Khoja et al., 2014). However, it has been demonstrated that utilising multiple 
markers can improve the sensitivity when compared to individual marker assays (Freeman 
et al., 2012). On the other hand, negative selection isolates CTCs by removing leukocytes 
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through the targeting of CD45, leaving CTCs and a background of white blood cells (WBCs) 
(Joshi et al., 2014). 
Label-free methods provide another option for CTC isolation by separating cells based on 
their physical properties. These techniques often target cells based on their size, 
deformability and density as CTCs are predominantly larger, stiffer and less dense than 
leukocytes (Alix-Panabieres and Pantel, 2014; Aya-Bonilla et al., 2017). As with label-
dependent isolation methods, there are a variety of different label-free isolation systems 
that use different techniques to separate the CTCs form the blood. Two of such systems for 
the label-free detection of CTCs are the ClearCell FX system (Clearbridge BioMedics) and the 
Parsortix system (Angle plc). 
The ClearCell FX system is a microfluidic device that utilises a spiral chip to isolate CTCs 
based on size using centrifugal forces. When pumped through the spiral chip smaller cells 
migrate to the outer wall while larger cells, such as CTCs, move to the inner wall. The 
separate cell colonies are collected into different outlets after passing through the spiral, 
providing isolated CTCs (Figure 10) (Chudasama et al., 2016; Hou et al., 2013). 
 
Figure 10. Diagram depicting the inner workings of a ClearCell machine, Adapted from (Hou et al., 
2013). 
The Parsortix system is a microfluidic device that separates CTCs using a series of steps over 
which cells are forced, leading to a final gap of 10μm. Leukocytes and erythrocytes pass 
through the gap and are flushed out of the system while the larger, rigid CTCs are captured 
and harvested at the end of the process (Figure 11) (Xu et al., 2015). 
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Figure 11. Diagram depicting the inner workings of the Parsortix machine (Xu et al., 2015). 
No matter which method of CTC enrichment is used, there will still be a number of 
leukocytes remaining in the sample. It is therefore necessary to be able to detect CTCs and 
differentiate them from leukocytes, allowing the identification and visualisation of 
individual CTCs (Pantel and Alix-Panabieres, 2012). As with the isolation techniques, there 
are a variety of different methods that can be used to distinguish CTCs from leukocytes. 
Cells are often stained via immunocytochemistry techniques, using antibodies known to be 
specific to markers expressed on cancer cells. A cocktail of melanoma markers can be used 
to identify melanoma CTCs (Aya-Bonilla et al., 2017), while cytokeratin and EpCAM can be 
used to identify CTCs from carcinomas such as NSCLC (Adams et al., 2017; Kallergi et al., 
2018; Nicolazzo et al., 2016). Cells are considered to be CTCs if they positively stain for tissue 
of origin, tumour-cell specific markers while remaining negative for CD45, which should only 
be found on leukocytes and granulocytes (Joosse et al., 2015; Khoja et al., 2014). 
1.6. Expression of PD-L1 on CTCs 
As stated above, PD-L1 expression in tumour biopsies is correlated with response to anti-
PD-1 therapy. However, to identify PD-L1 on patient tissue, biopsies are taken from a single 
tumour, at a single time point. This means that biopsies are not able to account for changes 
in the tumour over time, or heterogeneity between tumours. Both of these problems could 
potentially be addressed by analysing the expression of PD-L1 on CTCs. Due to the fact that 
they arise from tumours, it is believed that CTCs are likely to share the same immune escape 
mechanisms, such as PD-L1 expression (Nicolazzo et al., 2016). Moreover, since CTCs may 
arise from any or all current tumours in a patient at any one time, they are more likely to 
be representative of the tumours at a given time point (Figure 12). 
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Figure 12. Model of expression of programmed cell death ligand-1 (PD-L1) on circulating tumour 
cells (CTCs) derived from heterogeneous tumours. CTCs represent the sum of all tumours in a patient 
at the time of blood collection. 
1.6.1. PD-L1 expression on NSCLC CTCs 
A total of nine studies addressing the expression of PD-L1 on CTCs have been published to 
date. Among these nine publications, the number of patients with CTCs (referred herein as 
CTC detection rate) varied between 22% and 100% at both baseline and after front-line 
therapy. Several different methods were employed for the isolation and detection of CTCs, 
making it difficult to compare the results between studies. Three studies employed the size 
of epithelial tumour cells (ISET) platform (Guibert et al., 2018; Ilié et al., 2017; Kallergi et al., 
2018), while all other studies employed different types of methodologies such as the 
CellSearch System (Nicolazzo et al., 2016), the Epic CTC platform (Boffa et al., 2017), Vortex 
high throughput (HT) technology (Dhar et al., 2018), graphene oxide (GO) Chip (Wang et al., 
2019), spiral microfluidic technology (Kulasinghe et al., 2019), and the CellSieve 
Microfiltration Assay (Adams et al., 2017) (Table 1). Despite differences in CTC detection rates 
and methodologies, these studies indicate that the detection of CTCs provides potential for 
predictive assessment in advanced NSCLC, in agreement with previous literature (Normanno 
et al., 2016). 
All studies reported on the presence of PD-L1 expressing CTCs in NSCLC patients, with 
detection rates ranging between 2.0% and 96.8%. Three studies evaluated PD-L1+ CTC in 
patients undergoing anti-PD-1 therapy (Dhar et al., 2018; Guibert et al., 2018; Nicolazzo et 
al., 2016), with only two of them evaluating whether PD-L1 expression on CTCs can serve as 
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a predictive biomarker of response (Dhar et al., 2018; Guibert et al., 2018). Four studies 
evaluated the dynamics of PD-L1 expression on CTCs prior to treatment and after treatment 
initiation (Adams et al., 2017; Kallergi et al., 2018; Nicolazzo et al., 2016). However, only two 
studies compared the expression of PD-L1 on CTCs with that on matching tumour tissue 
(Guibert et al., 2018; Ilié et al., 2017). All but one study was single centred, conducted in non-
metastatic NSCLC patients with cohort sizes varying from a total of 13 to 112 NSCLC patients 
(Table 1). 
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Table 1. Prospective studies evaluating programmed cell death ligand-1 (PD-L1) on circulating tumour cells (CTCs) in NSCLC. 
Reference 
(Sample Size)  
Detection 
Method Therapy Stage 
Tumour 
Tested for PD-
L1 Expression 
Time Point  
of Blood Draw/ 
Method of Staining 
Criteria for CTC 
Identification 
Detection Rates 
of CTCs 
Detection Rates of 
PD-L1+ CTCs 
Anti-PD-L1 
Antibody Prognostic/Predictive (Cut-Off Value) 
Nicolazzo et 
al., 2016 
(Nicolazzo et 
al., 2016) (n = 
24) 
CellSearch  Nivolumab Stage IV NSCLC No 
Baseline 3 months 6 
months 
IF 
CK+/EPCAM+/DAPI+ and 
PD-L1± 
20/24 (83.0%)  
10/15 (66.7%) 
10/10 100.0%) 
19/20 (95.0%) 
10/15 (66.7%) 
10/10 (100%) 
130021 (R&D 
system) NE 
*Boffa et al., 
2017 (Boffa et 
al., 2017)  
(n = 112) 
Epic Sciences 
CTC detection 
plates 
Treatment-naïve  Stage I–IV  NSCLC No 
Treatment naïve 
IF CK
+/CD45−/DAPI+ /PD-L1+ 112/112 (100%) 26/112 (23.0%) 
EIL3N (Cell 
Signalling 
Technology) 
Prognostic (>1.1 PD-L1+ CTC/mL) 
[HR = 3.85 (1.64–9.09); p = 0.002)] 
Ilie et al., 
2017 (Ilié et 
al., 2017) 
(n = 106) 
ISET platform; 
Rare cells 
99-Chemotherapy 
naïve and  
7-neoadjuvant 
chemotherapy 
Stage III–IV Yes Baseline IF 
Circulating non-
haematological cells with 
malignant features 
(CNHC-MF] 
80/106 (75%) 6/71 (8.0%) SP142 (Ventana) 
Not Prognostic (no PD-L1+ CTC/mL) 
PFS: HR: 1.452, (0.82–2.58), and stage-
adjusted HR: 1.36, (0.77–2.42)].   
OS: HR: 1.55, (0.7–3.470),  
and stage-adjusted HR: 1.42, (0.63–3.31)]. 
Adams et al., 
2017 (Adams 
et al., 2017) 
(n = 41) 
Cell Sieve 
Microfiltration 
Assay 
Chemotherapy 
Radiotherapy 
Stage I–IV 
NSCLC Yes 
Baseline (T0)  
Post-induction 
of Radiotherapy (T1) 
IF 
CK+/EPCAM+/DAPI+ 35/41 (85.0%) 41/41 (100%) 
35/41 (85.0%) 
41/41 100%) 
130021 (R&D 
system) for CTCs  
22C3 and 28-8 
(DAKO pharmDX) 
for tissue biopsies 
Not Prognostic (≥2 PD-L1+ CTC/mL) 
At T0, PFS: HR = 1.8, p = 0.305   
At T1, PFS: HR = 0.7, p = 0.581 
Guibert et al., 
2018 (Guibert 
et al., 2018) 
(n = 96) 
ISET platform; 
Rare cells Nivolumab 
Stage IV 
NSCLC Yes 
Baseline Post cycle 1 
IF 
DAPI+/CD45−/Cytomorph
ometric malignant 
features 
89/96 (93.0%) 
23/24 (95.8%) 
74/89 (83.0%) 
23/23 (100%) 
EIL3N (Cell 
Signalling 
Technology) 
Not Predictive  
At ≥ 1% PD-L1+ CTC/mL; HR = 1.21(0.64–2.27), 
p = 0.55 
At ≥ 5% PD-L1+ CTC/mL; HR = 1.05(0.59–1.88), 
p = 0.55] 
At ≥ 5% PD-L1+ CTC/mL; HR = 0.75(0.45–1.25), 
p = 0.27 
Dhar et al., 
2018 (Dhar et 
al., 2018) 
(n = 21) 
Vortex HT 
Technology 
Nivolumab/Pembro
lizumab 
Stage IV 
NSCLC Yes 
Baseline 
IF 
CK+/DAPI+/CD45− or 
CK+/DAP+/CD45−/cytopat
hological features 
14/31 (45.2%)  12/14 (85.7%) 4059 (ProSci Inc.) Not predictive (≥2 PD-L1
+ CTC/mL)  
PFS: HR = 0.83 (0.24–2.84, p = 0.764) 
Kallergi et al., 
2018 (Kallergi 
et al., 2018) 
(n = 30) 
ISET platform; 
Rare cells 
Chemotherapy-
naïve  
Stage IV 
NSCLC No 
Baseline Post cycle 1 
Giemsa  CK
+/CD45−/PD-L1+ 28/30 (93.3%)  9/11 (81.8%)  8/30 (26.7%) 
5/11 (45.5%) 
EH 12.2H7 
(Biolegend) 
B7-H1/PD-
L1/CD274 (Novus 
Biological) 
NE Baseline Post cycle 1 
IF  
17/30 (56/7%) 
8/11 (72.7%) 
Wang et al., 
2019 (Wang 
et al., 2019) 
(n = 13) 
GO chip 5-radiation 8-chemoradiation Stage I–III No 
Baseline (visit 1) 
Visit 2 
Visit 3 
IF 
CK+/CD45−/DAPI+ 
13/13 (100%) 
12/13 (92.3%) 
13/13(100%) 
6/13 (46.2%) 
10/13 (76.9%) 
6/13 (46.2%) 
329702 
(BioLegend) 
PFS analysed (≥5% PD-L1+ CTC/mL 
Log rank p = 0.017  
HR not provided 
Kulasinghe et 
al., 2019 
(Kulasinghe et 
al., 2019) 
(n = 35) 
Spiral 
Microfluidic 
Technology 
Treatment-naïve  Stage III–IV No Baseline IF 
CK+/CD45−/DAPI+/ 
PD-L1+ 18/35 (51.4%) 10/18 (55.6%) 28-8 (Abcam) NE 
IF: immunofluorescence, NSCLC: non-small cell lung cancer, HR: hazard ratio, NE: prognostic or predictive significance not evaluated, ISET: size of epithelial tumour cells, EpCAM: 
epithelial cell adhesion molecules, CK: cytokeratin, PFS: progression free survival. * prospective multi-institutional study. 
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Boffa et al. described the only multi-institutional prospective study reported to date 
evaluating PD-L1 expression on CTCs in 112 treatment naïve NSCLC patients, the largest 
sample size analysed to date. PD-L1+ CTCs were detectable in the peripheral blood of 23% of 
NSCLC patients assessed prior to therapy. While most of the circulating cells identified in this 
study met the consensus criteria for CTCs—expression of epithelial protein, absence of CD45 
expression, and an intact nucleus—many PD-L1+ CD45− cells in patient samples contained 
both a nuclear morphology distinct from surrounding WBCs and other CTCs and with 
expression of CK below the analytical cut-offs of the assay. These cells were not observed in 
healthy controls and have not been genetically confirmed to be of malignant origin; therefore, 
the authors refrain from labelling them as “CTCs” and adopted the nomenclature circulating 
cells associated with malignancy (CCAMs). Within the PD-L1+ CCAM population (47 cells from 
26 NSCLC patients), two distinct subpopulations were noted based on differential expression 
of cytokeratin (CK). Nineteen (40%) cells were positive for CK [PD-L1+ CK+], whereas 60% were 
negative for CK [PD-L1+ CK−]. 
Ilie et al. investigated the utility of CTCs as a non-invasive biomarker to evaluate PD-L1 status 
in 106 advanced NSCLC patients. CTCs were detected in 75% of patients. PD-L1 staining was 
assessed in 71 samples that showed >1 CTCs, but only 8% of NSCLC patients exhibited PD-L1+ 
CTCs (Ilié et al., 2017). 
Adams et al. tracked PD-L1 expression in circulating tumour and stromal cells in 41 stage I–IV 
NSCLC patients undergoing radiotherapy. CTCs were identified in 85% and 100% of patient 
samples prior to (T0) and after radiotherapy (T1), respectively. Three different patterns of the 
expression of PD-L1 between T0 and T1 were observed in 35 patients who were assessable 
for both time points. Eleven patients (32%) showed a rise in PD-L1 expression scores from T0 
to T1, 18 patients (51%) had no/low PD-L1 expression, and 6 patients (17%) had persistently 
medium/high PD-L1 at the two-time points. Of note, the authors characterised the two most 
common CTC subtypes undergoing epithelial-to-mesenchymal transition (EMTCTC); the 
prognostically relevant pathological definable CTCs (PDCTC); and a subtype of circulating 
stromal cells, cancer-associated macrophage-like cells (CAMLs). CAMLs were the most 
prevalent at both times points (at baseline and after induction of treatment) followed by 
EMTCTCs and PDTCTCs. Both CAMLs and EMTCTCs have been well proven as cancer-specific 
biomarkers; therefore, data obtained from the study demonstrated that combining CAMLs 
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and EMTCTCs significantly expands the capacity to characterise cellular biomarkers such as 
PD-L1 in blood-based diagnosis (Adams et al., 2017). 
Guibert et al. monitored the expression of PD-L1 on CTCs among 96 NSCLC patients treated 
with nivolumab. CTCs were detected in 93% of patients’ samples at baseline, and they found 
that 83% of the patients had PD-L1+ CTCs on at least 1% of CTCs prior to therapy. At the time 
of progression, 95% of analysed CTC-positive patients had PD-L1+ CTCs, of whom 83% had 
more than 10% of CTCs as PD-L1+, compared with 68% of pre-treatment CTCs (Guibert et al., 
2018). 
Dhar et al. evaluated PD-L1 expression on CTCs among patients receiving nivolumab therapy 
prior to or during treatment. The study evaluated CTCs from 31 samples collected from 22 
patients. They observed that 96.8% of the patient samples had at least 1 CTC and 48.4% of 
samples had at least 10 CTCs. Using a cut-off criterion of 1.32 CTCs/mL of blood, based on the 
analysis of 10 healthy controls, they concluded that 14 of 31 patient samples were positive 
for CTCs. Among patient samples with CTCs, 85.7% had one or more PD-L1+ CTCs (Dhar et al., 
2018). 
Nicolazzo et al. evaluated the presence of PD-L1+ CTCs longitudinally, at three-month intervals 
during therapy in 24 metastatic NSCLC patients. All patients analysed underwent anti-PD-1 
therapy through an expanded access program for nivolumab. CTCs were detected in 83% 
patients and PD-L1+ CTCs were detected in 19 of 20 patients with detectable CTCs at baseline. 
Ten out of 15 patients with detectable CTCs after three months from starting therapy had PD-
L1 expressing CTCs, and 5 of 10 patients with detectable CTCs after six months of treatment 
had PD-L1+ CTCs. It was observed that both baseline and at three months after treatment 
initiation, almost all CTCs expressed PD-L1, irrespective of clinic-pathological characteristics 
(Nicolazzo et al., 2016). 
Kallergi et al. investigated PD-L1 expression on CTCs isolated from 30 NSCLC patients treated 
with chemotherapy. CTCs were evaluated by Giemsa staining and immunofluorescence (IF). 
Giemsa staining revealed that 28 of 30 patients and 8 of 11 patients had detectable CTCs 
before and after their third chemotherapy cycle, respectively, while IF could detect CTCs in 
17 of 30 (56.7%) chemo-naïve patients and in 8 of 11 patients after the third chemotherapy 
cycle. The rate of PD-L1+ CTC detection in the group of patients was 26.7% at baseline and 
45% after three cycles of front-line chemotherapy in the whole patient group (Kallergi et al., 
2018). 
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Wang et al. monitored the dynamic changes of the expression of PD-L1 in CTC in 13 non-
metastatic NSCLC patients treated with radiotherapy or chemoradiation. CTCs were detected 
in all patients throughout the course of treatment and PD-L1+ CTCs were found in 25 out of 
38 samples collected with an average of 4.5 cells/mL. All patients who received radiation only 
had significantly increased numbers of PD-L1+ CTCs during treatment and, similarly, 7 out of 
8 non-metastatic NSCLC patients showed increased numbers of PD-L1+ CTCs with concurrent 
chemotherapy (Wang et al., 2019). 
Kulasinghe et al. phenotypically characterised CTCs in 35 stage IV NSCLC patients for clinically 
actionable targets. The authors identified CTCs or CTC clusters in 74% of the patients. Using 
the presence of at least one PD-L1 positive cell as the cut-off for PD-L1 positivity, 10 out of 18 
NSCLC patients expressed PD-L1 in CTCs (Kulasinghe et al., 2019). 
Altogether, these studies demonstrate that analysis of PD-L1 on CTCs is feasible and could be 
detected prior to and after frontline therapy. We should underscore that two studies (Adams 
et al., 2017; Wang et al., 2019) reported that PD-L1 expression is significantly increased in 
patients after radiotherapy, which is consistent with reports from preclinical studies (Deng et 
al., 2014; Dovedi et al., 2014). 
1.6.1.1. PD-L1 expression on CTCs as prognostic marker in NSCLC 
Several studies have reported that PD-L1 expression in tumour tissue is associated with either 
shorter or longer survival time in NSCLC patients (Pan et al., 2015; Velcheti et al., 2014; Wu 
et al., 2015; Zhang et al., 2016). The prognostic value of PD-L1+ CTCs in NSCLC was analysed 
in four of the nine studies identified (Table 1) (Adams et al., 2017; Boffa et al., 2017; Ilié et al., 
2017; Wang et al., 2019). Only two studies demonstrate a statistically significant difference in 
survival probabilities between patients with PD-L1+ CTCs (Boffa et al., 2017; Wang et al., 
2019). 
Boffa et al. reported that NSCLC patients with >1.1 PD-L1+ CTCs/mL of blood at diagnosis had 
worse two-year survival compared with those with ≤1.1 PD-L1+ CTCs/mL (31.2% vs. 78.8%, p 
= 0.002). A multivariable Cox proportional hazard model controlling for staging indicated that 
the number of PD-L1+ CTCs/mL is a significant independent predictor of mortality (HR = 3.85; 
95% CI, 1.64–9.09; p = 0.002) (Boffa et al., 2017). On the other hand, Wang et al. showed that 
patients with >5% PD-L1 expression on CTCs had significantly shorter PFS compared with PD-
L1 negative patients (median 7.1 months vs. median not reached: p = 0.017). However, no 
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Cox regression analysis was performed nor multivariate analyses to control for other 
predictors of progression (Wang et al., 2019). 
It is important to note that none of the four studies analysed patients treated with anti-PD-
1/PD-L1 therapy. 
1.6.1.2. PD-L1 expression on CTCs as a predictive marker in NSCLC 
Three of the studies highlighted here explored PD-L1 expression on CTCs in association with 
the response to PD-1 inhibitors (Dhar et al., 2018; Guibert et al., 2018; Nicolazzo et al., 2016). 
Only Guibert et al. correlated PD-L1+ CTCs with the response to PD-1 inhibitor, nivolumab in 
a large cohort of NSCLC patients (n = 96). The presence of PD-L1+ CTCs prior to treatment at 
different thresholds had no statistically significant impact on PFS. Opposite to what would be 
expected, patients with >1% PD-L1+ CTCs at baseline were frequently non-responders 
compared with patients who had PD-L1− CTCs (47/69 (68%) vs. 6/15 (40%), p = 0.04) (Guibert 
et al., 2018). Similarly, Dhar et al. analysed the association between PD-L1 expression and PFS 
in 17 patients prior to starting treatment. They found that having ≥2 PD-L1+ CTCs was not a 
predictor of response or clinical benefit, though this small cohort included patients treated 
with nivolumab as well as pembrolizumab (Dhar et al., 2018). Nicolazzo et al. did not 
specifically address the predictive significance of PD-L1 in CTCs in their study. Nevertheless, 
PD-L1+ CTCs were identified in 19 patients at baseline, and only 5 of them (26%) achieved 
clinical benefit after six months of treatment. Thus, PD-L1+ CTCs were not demonstrated to 
be a predictor of response to therapy (Nicolazzo et al., 2016). 
Overall, no report to date has shown evidence on the predictive value for PD-L1+ CTCs for 
response to anti-PD1 agents. 
1.6.1.3. Correlation between PD-L1 expression on tumour biopsy tissue and 
CTCs in NSCLC patients 
Four studies explored the correlation between the expression of PD-L1 on CTCs and its 
expression in tumour tissue biopsies (Adams et al., 2017; Dhar et al., 2018; Guibert et al., 
2018; Ilié et al., 2017). The largest reported study to date (n = 71) was conducted by Ilié et al., 
who noted 93% concordance between PD-L1 expression on CTCs and matched tumour tissues 
(Ilié et al., 2017). In contrast, Guibert et al. found no statistically significant correlation 
between the expression of PD-L1 on archived tissue and CTCs (n = 66), with the observed rate 
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of concordance being 45% (Guibert et al., 2018). The other two studies only presented 
descriptive data indicating some concordance between PD-L1 expression on CTCs and 
matched tumour tissue. However, they had a limited sample size (n = 9 and n = 4), which 
prevented appropriate statistical analysis from being performed (Adams et al., 2017; Dhar et 
al., 2018). 
Generally, these studies demonstrated the feasibility of comparing PD-L1 expression on CTCs 
and matched tumours; however, the findings from these studies are not directly comparable 
because of the different anti-PD-L1 monoclonal antibodies used between CTCs and matched 
tumours, and different antibodies used between studies. Adams et al. used three anti-PD-L1 
monoclonal antibodies for staining, with clone 130021 (R&D Systems, Minneapolis, MN, USA) 
being used for CTCs, while matched tumours were stained with either the anti-PD-L1 clone 
28.8 (DAKO) or the clone 22C3 (DAKO). Similarly, Dhar et al. used two different antibodies, 
with an anti-PD-L1 antibody (ProSci Inc Ref# 4059, Poway, CA, USA) being used to stain CTCs 
and the anti-PD-L1 clone SP142 (Ventana) being used for matched tissues. Ilié et al. used an 
anti-PD-L1 monoclonal antibody clone SP142 for PD-L1 staining both on CTCs and matched 
tumour tissue, while Guibert et al. used the anti-PD-L1 rabbit monoclonal antibody clone 
E1L3N (Cell Signalling Technology, Danvers, MS, USA). The use of different antibodies 
between studies may explain the discrepancies in results. 
Four different PD-L1 immunohistochemistry (IHC) assays (PD-L1 assays (22C3, 28-8, SP142, 
SP263) have been approved by the United States Food and Drug Administration as companion 
diagnostic tests for tissue staining. Reports from phase I of the blueprint study (BPI) by Hirsh 
et al., 2017 revealed that three of the four antibodies (22C3, 28-8, SP263) demonstrate similar 
analytical performance for tumour cell staining, whereas the fourth (SP142) provides 
significantly lower staining for tumour proportion score (Hirsch et al., 2017). Recently, results 
obtained from phase II of the blueprint PD-L1 IHC assay (BP2) study using real-life clinical lung 
cancer samples affirmed the result of BP1 and consolidated the evidence for 
interchangeability of three different assays (22C3, 28-8, and SP263) (Tsao et al., 2018). 
Compared with the above-mentioned studies, these findings demonstrate that the best 
approach for comparing PD-L1 IHC testing is to perform the test with assays that have 
undergone rigorous analytical and clinical validation. Similar studies will be needed to develop 
standardised methods for PD-L1 assessment on CTCs. 
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1.6.2. Expression of PD-L1 on melanoma CTCs  
To date there have been only two published studies assessing PD-L1 expression on CTCs in 
melanoma patients (Khattak et al., 2019; Po et al., 2019). Po et al. enriched for melanoma 
CTCs from 9mL of blood using immunomagnetic beads coated with either MCAM, MCSP or 
both, and detected them using immunocytochemistry (Po et al., 2019). Po et al. utilised a 
combination of Melan-A, gp100 and S100 antibodies to identify melanoma CTCs, CD45 to 
exclude WBCs and the E1L3N antibody clone for PD-L1 expression. MCAM conjugated beads 
isolated CTCs from 10/16 patients, MCSP conjugated beads isolated CTCs from 13/16 patients 
and combined MCAM & MCSP conjugated beads isolated CTCs from 14/16 patients (Po et al., 
2019). MCAM beads isolated fewer CTCs than both MCSP and MCAM/MCSP combination 
beads, with the median CTC counts being 2.5, 9 and 16 respectively per patient (Po et al., 
2019). PD-L1 was assessed on 13 patients with detectable CTCs, PD-L1 positive CTCs were 
identified in 5/13 patients with the percentage of PD-L1 expressing CTCs ranging from 1.5% 
to 60% (Po et al., 2019). 
Khattak et al. did not perform CTC enrichment. Instead peripheral blood mononuclear cells 
(PBMCs) from 8mL of blood were then stained with a multimarker antibody  panel targeting 
MCAM, MCSP, ABCB5, CD271 and RANK to identify tumour cells, CD45 and CD34 to identify 
WBCs and circulating endothelial cells, and PD-L1 (Khattak et al., 2019). CTCs were detected 
in 25/40 patients with the CTC number ranging from 7 to 291 cells. PD-L1 was identified on 
CTCs from 16/25 patients with detectable CTCs with the percentage of PD-L1 expressing CTCs 
ranging from 1% to 89% (Figure 15) (Khattak et al., 2019). 
1.6.2.1. Clinical benefit of PD-L1 expression on CTCs in melanoma 
The study published by Khattak et al. is the only report to date to assess the clinical benefit 
of PD-L1 expression on CTCs in melanoma patients. For patients with detectable CTCs, those 
with PD-L1 expressing CTCs had a significantly longer progression free survival compared to 
those with only PD-L1 negative CTCs (HR 0.162, 95% CI 0.042-0.631, P = 0.009, Figure 13a). 
The median PFS for the PD-L1 negative CTCs group was 5.5 (5.2-5.8) months, while median 
PFS was not reached for the group with PD-L1 positive CTCs. The 12-month PFS rates were 
81% vs. 22% in the PD-L1 positive vs. PD-L1 negative CTCs groups, respectively (P = 0.034). 
Interim overall survival analysis did not reveal statistically significant differences between the 
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groups, although survival rates were lower in patients with PD-L1- CTCs (Figure 13b), with 
median OS not reached in the group with PD-L1+ CTCs (Khattak et al., 2019). 
Multivariate Cox regression analysis controlling for age, sex, line of therapy, disease stage, 
BRAF status, ECOG status, neutrophil-to-lymphocyte ratio (NLR) and presence of liver 
metastases confirmed that CTC PD-L1 positivity is an independent predictive biomarker of PFS 
(HR 0.11, 95% CI 0.01-0.81, P = 0.03) (Khattak et al., 2019). 
 
Figure 13. Kaplan-Meier plots of progression-free survival and overall survival according to PD-L1 
expression on CTCs prior to treatment initiation. (A): Progression-free survival. (B): Overall survival. 
Abbreviations: CI, confidence interval; CTC, circulating tumour cell; HR, hazard ratio (Khattak et al., 
2019). 
1.6.2.2. PD-L1 expression on CTCs as a predictive marker in melanoma 
The study by Khattak et al. in 2019 is also the only published study to assess CTC PD-L1 
expression as a predictive marker in melanoma patients. Patients in the study were treated 
with pembrolizumab monotherapy, with 21 responders and 19 non-responders. The total 
number of CTCs was similar and did not significantly differ between responders and non-
responders, and there were no differences in PFS or OS between patients with detectable and 
non-detectable CTCs. However, the number of PD-L1 positive CTCs was significantly higher in 
responders (P=0.005, Figure 14). Amongst patients with detectable CTCs, patients with PD-L1 
positive CTCs were eight times more likely to be responders compared to patients with no 
PD-L1 positive CTCs [OR 8.67 (95% CI 1.19-342.96), P = 0.017) (Khattak et al., 2019). 
Comparison of CTCs detected at baseline and after 6-12 weeks post treatment initiation 
(follow up), showed that the total number of CTCs, as well as the proportion of CTC expressing 
PD-L1, decreased upon treatment in most responders, and increased or remained the same 
in most non-responders (Khattak et al., 2019). 
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Khattak et al. demonstrated that PD-L1 expression on CTCs is an independent predictor of 
response and prolonged PFS in melanoma patients treated with pembrolizumab. This study 
provided a proof of concept that detection of PD-L1 status through liquid biopsy can provide 
clinically relevant information (Khattak et al., 2019). 
 
Figure 14. Comparison of total and PD-L1+ CTCs in responders and non-responders to pembrolizumab 
treatment. (A): Total CTCs. (B): PD-L1+ CTCs. Abbreviations: CTC, circulating tumour cell; R, responder. 
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1.7. Theoretical framework 
Immune checkpoint inhibitors, in particular anti-PD-1 antibodies, are a relatively new 
treatment option that have significantly altered clinical management of late stage melanoma 
and NSCLC patients. These new treatments are highly successful in a subset of patients, 
however, there are a number of patients that do not respond. Moreover, treatment with 
these antibodies are associated with high grade adverse events (Yuan et al., 2016). The 
combination of anti-PD-1 and anti-CTLA4 therapies has frequently been used as a means to 
increase effectiveness (Ascierto et al., 2017; Gide et al., 2019). Clinical trials have also tested 
anti-PD-1 therapy in combination with other checkpoint inhibitors such as anti-Tim-3 and 
anti-LAG3 (Zou et al., 2016), and co-stimulatory factors such as glucocorticoid-induced TNFR 
family related gene, CD134 and CD137 (Hellmann et al., 2016; Perez-Ruiz et al., 2017). Where 
these combinations are not FDA approved, anti-PD-1 therapy in combination with 
chemotherapy has been approved by the FDA to treat NSCLC patients (Langer et al., 2016; 
Paz-Ares et al., 2018; Sheela et al., 2018). However, combination therapies are often more 
expensive and more toxic when compared to monotherapy, and so should be avoided if 
monotherapy could be found to be effective.  
PD-L1 is one of the biomarkers that can potentially be used to predict response to treatment 
with anti-PD-1 antibodies. PD-L1 binds to PD-1 and this interaction acts to suppress the 
immune system and so provides an evasion mechanism to tumours that express the protein 
(Yuan et al., 2016). CTCs can be obtained without invasive surgery, display tumour specific 
markers such as PD-L1, can be used to monitor disease progression in real time and can be 
evaluated after failure of first line treatment (Carter et al., 2017; Nicolazzo et al., 2016; Scher 
et al., 2016). While a limited number of studies have been published detailing PD-L1 
expression on CTCS in NSCLC patients, even fewer studies have been published detailing PD-
L1 on melanoma CTCs. Only a single study compared CTC PD-L1 expression and tumour PD-
L1 expression for melanoma and a limited number have been published for NSCLC (Adams et 
al., 2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et al., 2017; Khattak et al., 2019). This 
information would enable more efficient treatment selection for melanoma patients and 
would provide details of dynamic PD-L1 expression levels closer to treatment initiation for 
both NSCLC and melanoma patients. 
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This study established a method to characterise PD-L1 expression in CTCs using fluorescence 
immunocytochemistry and investigated PD-L1 expression in CTCs relative to tumour biopsies 
from NSCLC and melanoma patients. These results will enable further studies that ascertain 
the relation between PD-L1 expression in CTCs and patient response to immunomodulatory 
antibodies targeting the PD-1 immune checkpoint. 
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1.7.1. Hypothesis 
PD-L1 expression on melanoma and NSCLC CTCs can be identified and evaluated by 
immunocytochemistry. 
1.7.2. Specific Aims 
1. Compare PD-L1 expression on melanoma CTCs, assessed by flow cytometry, to 
matched tissue samples; 
A cohort of melanoma patients from an earlier study had PD-L1 assessed on CTCs using 
flow cytometry. Matched tissue samples for this cohort of melanoma patients were 
obtained, stained by immunohistochemistry and given a PD-L1 score. Tissue PD-L1 scores 
were then compared to the CTC PD-L1 data. 
2. Develop an immunocytochemistry assay to evaluate PD-L1 expression in melanoma 
CTCs; 
The 28.8, 22C3 and 130021 PD-L1 antibodies were assessed for PD-L1 detection to identify 
the most suitable candidate for incorporation into an immunocytochemistry panel. Cell 
lines to be used as positive (high and low PD-L1 expression) and negative controls were 
then identified using flow cytometry and used in the development of a multimarker 
immunocytochemistry panel to identify PD-L1 expression on melanoma CTCs. The final 
protocol was then validated in a small cohort of melanoma patients. 
3. Develop an immunocytochemistry assay to evaluate PD-L1 expression in carcinoma 
CTCs; 
Carcinoma cell lines to be used as positive (high and low PD-L1 expression) and negative 
controls were identified using first by flow cytometry and then used in the development 
of a multimarker immunocytochemistry panel to identify PD-L1 expression on carcinoma 
CTCs. The protocol was then validated in a small cohort of non-small cell lung cancer 
patients. PD-L1 expression on NSCLC CTCs was then compared to expression in matched 
tissue samples. 
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2. CHAPTER 2: Materials and 
Methods 
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2.1. Aim 1: Compare PD-L1 expression on melanoma CTCs, assessed by flow 
cytometry, to matched tissue samples 
2.1.1. Comparing tumour and CTC PD-L1 expression 
Immunohistochemistry for PD-L1 expression was performed in a Dako ASL48 Autostainer as 
described previously (Ye et al., 2019), using the PD-L1 IHC 22C3 pharmDx (Dako, Carpinteria, 
CA) and approved by the US FDA for use in NSCLC (Herbst et al., 2016). Verification of 
successful reaction on each slide was assessed with tonsil and placenta as external tissue 
controls. PD-L1 expression was assessed based on the Tumour Proportion Score (TPS) by an 
experienced pathologist (Dr Benhur Amanuel). Only viable tumour cells were assessed, 
positivity is defined as any perceptible linear cell membrane staining (partial or complete), 
the score reflects percentage of positive tumour cells, and any associated immune cells are 
excluded from scoring. 
A two-sided Fisher’s exact test was performed to compare response relative to PD-L1 
expression on tumour tissue and to PD-L1 expression on CTCs or tumour tissue. 
2.2. Aim 2: Develop an immunocytochemistry assay to evaluate PD-L1 
expression in melanoma CTCs 
2.2.1. Cell lines 
Melanoma cell lines (MP41, SKMEL28, A2058, UACC62, WM164 & WM793) were maintained 
in cell culture media as a monolayer at 37 °C and 5% CO2. Cell lines were cultured in either 
DMEM (ThermoFisher Scientific, Waltham, United States of America) or RPMI 1640 
(ThermoFisher Scientific), each containing 10% - 20% foetal bovine serum (ThermoFisher 
Scientific) as required. In preparation for flow cytometry or immunofluorescent staining, cells 
were grown until 80% confluent.  
To increase PD-L1 expression, SKMEL28 cells were incubated with varying concentrations (10 
to 100ng/ml) of IFN-γ for 24 hours to induce PD-L1 expression. 
2.2.2. PD-L1 expression assessment by flow cytometry 
The level of PD-L1 expression for each cell line was first assessed by flow cytometry using the 
rabbit anti-human PD-L1 antibody clone 28.8 (Abcam, Cambridge, United Kingdom).  
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Cells were harvested from flasks using Trypsin/EDTA (ThermoFisher Scientific) and washed in 
phosphate buffered solution (PBS) once before counting. A total 1x104 cells were suspended 
in 100μL of FACS staining buffer (1% bovine serum albumin (BSA)/10% normal donkey serum 
(NDS) in PBS) containing the anti-PD-L1 antibody (clone 28.8, Abcam) diluted 1/100 for 30 
minutes. The cells were then washed once with 0.5% BSA/PBS before resuspending in FACS 
staining buffer containing a secondary donkey anti-rabbit IgG antibody conjugated to Alexa 
Fluor® 488 (Abcam) diluted 1/500 for 30 minutes. The cells were again washed once in 0.5% 
BSA/PBS before being resuspended in 100μL of FACS staining buffer and analysed using a 
Gallios Flow Cytometer (Beckman Coulter, Brea, United States of America).  
Table 2. Antibodies used for immunocytochemistry staining. 
 
2.2.3. WBC isolation from healthy volunteers 
Antibody Host Species Conjugate Clone 
Antigen 
location 
Supplier 
(CTLG #) Dilution Use 
gp100 Rabbit n/a EPR4864 Cytosol Abcam (ab137062) 1/50 
Melanoma CTC 
identification 
MLANA Rabbit n/a EP1422Y Cytosol Abcam (ab51061) 1/50 
Melanoma CTC 
identification 
S100 Rabbit n/a EP1576Y Cytosol Abcam (ab52642) 1/500 
Melanoma CTC 
identification 
PD-L1 Rabbit AF647 28.8 Membrane Abcam (ab209960) 1/100 
PD-L1 
expression 
PD-L1 Mouse n/a 22C3 Membrane DAKO (M365329-2) 1/100 
PD-L1 
expression 
PD-L1 Mouse FITC 130021 Membrane R&D Systems (FAB1561G) 1/100 
PD-L1 
expression 
Anti-rabbit 
IgG Donkey AF488 n/a n/a 
ThermoFisher 
Scientific  
(A-21206) 
1/500 Melanoma CTC identification 
CD16 Mouse PE 3G8 Membrane BioLegend (302008) 1/50 
WBC 
identification 
CD45 Mouse PE HI30 Membrane 
BD 
Biosciences 
(555483) 
1/50 WBC identification 
CK3-6H5 Mouse FITC CK3-6H5 Cytoskeleton 
Miltenyi 
Biotech 
(130-118-964) 
1/50 NSCLC CTC identification 
C11 Mouse AF488 C11 Cytoskeleton 
Cell Signalling 
Technology 
(4523S) 
1/100 NSCLC CTC identification 
AE1/AE3 Mouse AF488 AE1/AE3 Cytoskeleton 
ThermoFisher 
Scientific 
(53-9003-80) 
1/200 NSCLC CTC identification 
EpCAM Mouse FITC VU-1D9 Membrane 
ThermoFisher 
Scientific 
(MA1-10197) 
1/100 NSCLC CTC identification 
Vimentin Mouse AF647 V9 Cytoskeleton Abcam (ab195878) 1/1000 
NSCLC CTC 
identification 
PD-L1 Rabbit n/a 28.8 Membrane Abcam (ab205921) 1/400 
PD-L1 
expression 
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Healthy donors signed consent forms, previously approved by the Human Research Ethics 
Committees at ECU (No.11543 and No.21261). The blood was drawn by phlebotomists into 
vacutainer tubes, containing EDTA anticoagulant (Becton-Dickinson, Franklin Lakes, United 
States of America). The first 6ml of blood was collected in SST tubes for serum collection, 
doubling as a discard tube to avoid epithelial contamination. 
Red blood cells (RBCs) were lysed using RBC lysing buffer (140mM NH4Cl + 17mM Tris in 
ddH2O, pH 7.65) at a 1:5 volume ratio with continuous gentle mixing for 10 minutes at room 
temperature. The lysed RBCs were removed by centrifugation at 300g for 5 minutes. 
Following this, the nucleated cell fraction was washed once with PBS and finally resuspend in 
PBS. Cells were then counted and diluted into 10,000 cell fractions. 
2.2.4. Spiking of cancer cell lines 
Cell lines were spiked into WBC fractions in order to mimic cancer cells that could be present 
after CTC enrichment. For all immunocytochemistry spiking experiments involving WBCs, 
approximately 500 cells (from whichever cell line was required) were spiked into WBCs. 
Spiking melanoma cells involved diluting to the appropriate concentration of cells and mixing 
the fraction with a 10,000 WBC fraction, obtained from a healthy volunteer as described in 
2.2.3. 
2.2.5. Melanoma immunocytochemistry 
Cells (from CTC isolation/cell line spiked into WBC) were immediately fixed in 4% PFA for 10 
minutes. After that, cells were cytospun (Cytospin™ 4, Thermo Fisher Scientific) onto glass 
slides at 2000g for 5 minutes at medium acceleration. Cells were then dried and stored in a 
desiccator at 4°C or progressed straight to staining. 
Cells attached to the slides were incubated in blocking buffer (10% NDS/ 10% Glycine/ 5% 
Human FcR block/ 3% BSA/ 0.2% Triton X-100 (TX) in PBS) for 15 minutes before incubating in 
staining  buffer (10% NDS/ 3% BSA/ 0.2% TX in PBS) containing the diluted antibody mix (see 
Table 2 for details on antibody dilutions).  
For the final melanoma CTCs staining protocol was adapted from Aya-Bonilla et al. (Aya-
Bonilla et al., 2017), gp100 (clone EPR4864, Abcam), MLANA (clone EP1422Y, Abcam), S100 
(clone EP1576Y, Abcam), CD16 conjugated to phycoerythrin (PE) (clone 3G8, BioLegend, San 
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Diego, United States of America) and CD45 conjugated to PE (clone HI30, BD Biosciences, 
Franklin Lakes, United States of America) were incubated for 1 hour. Following this 
incubation, cells were washed three times for 5 minutes each in 1% BSA/PBS before 
incubating in stain buffer containing donkey anti-rabbit IgG antibody conjugated to Alexa 
Fluor® 488 dye (ThermoFisher Scientific) for 15 minutes. Cells were once again washed three 
times for 5 minutes each in 1% BSA in PBS before the final incubation in 10% normal rabbit 
serum (NRS)/10% NDS/ 3% BSA/ 0.2% TX in PBS containing PD-L1 conjugated to Alexa Fluor® 
647 (clone 28.8, Abcam) for 1 hour.  
Finally, cells were washed three times for 5 minutes each in 1% BSA in PBS, washed once in 
PBS for 5 minutes, dried and mounted with Fluoromount Gold plus DAPI (ThermoFisher 
Scientific).  
2.2.6. Patient recruitment 
Patients beginning treatment for metastatic melanoma were recruited by Professor Michael 
Millward (Sir Charles Gairdner Hospital, WA), Dr Adnan Khattak (Fiona Stanley Hospital, WA) 
and Dr Tarek Meniawy (Sir Charles Gairdner Hospital, St John of God Hospital, WA) prior to 
commencing therapy. Procedures were approved by Human Research Ethics Committees at 
Edith Cowan University (No. 18957) and Sir Charles Gairdner Hospital (No. 2013-246). Clinical 
data such as disease stage, prior therapy and forthcoming therapy was collected for all 
patients. At least 9mL of blood was collected from each patient into EDTA tubes for CTC 
analysis. Samples were processed within 24 hours of blood collection. 
2.2.7. CTC enrichment and immunofluorescent staining 
Blood samples (9 mL) were enriched from CTCs using the Parsortix system (Angle plc, 
Guildford, United Kingdom) as described previously (Aya-Bonilla et al., 2019). Enriched 
fractions were processed in accordance with the immunofluorescence staining method 
described for melanoma patients in section 2.2.5. Patient samples were periodically 
processed in tandem with high, medium and low PD-L1–expressing cell line controls to ensure 
consistent results. 
2.2.8. CTC identification and PD-L1 scoring 
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Stained slides were scanned using an automated inverted Eclipse Ti-E Nikon® fluorescence 
microscope to visualise immunofluorescent staining and analysis was performed using the 
NIS-Elements High Content Analysis software, version 4.2.01. Slides were scanned using; a 
DAPI filter with excitation and emission (Ex/Em) wavelengths of 395/460 nm with an exposure 
time of 300ms, a FITC only filter (Ex/Em = 470/535 nm) with an exposure time of 700ms and 
2x2 binning, a TRITC filter (EX/Em = 555/607 nm) with an exposure time of 500ms and 2x2 
binning, and a Cy5 filter (640/720 nm) with an exposure time of 1s and 2x2 binning. Look up 
tables, adjusted based on control slides, were used to remove background fluorescence and 
adjust displayed intensity appropriately.  
CTCs were identified among nucleated cell populations based on the size/morphology of cell, 
nuclear features and expression of melanoma markers in the absence of blood-lineage CD16 
or CD45 expression. Detectable PD-L1 expression was scored as high or low based on the 
negative control and low and high positive controls. 
2.3. Aim 3: Develop an immunocytochemistry assay to evaluate PD-L1 
expression in carcinoma CTCs 
2.3.1. Cell lines 
Cell lines (MCF7, MDA-MB-231 & LNCaP) were maintained in cell culture media as a 
monolayer at 37 °C and 5% CO2. Cell lines were cultured in either DMEM (ThermoFisher 
Scientific) or RPMI 1640 (ThermoFisher Scientific), each containing 10% - 20% foetal bovine 
serum (ThermoFisher Scientific) as required. In preparation for flow cytometry or 
immunofluorescent staining, cells were grown until 80% confluent. Some MCF7 cells were 
incubated with 100ng/ml IFN-γ for 24 hours to induce PD-L1 expression. 
2.3.2. PD-L1 expression assessment by Flow cytometry 
The level of PD-L1 expression for each cell line was first assessed by flow cytometry using a 
Gallios Flow Cytometer (Beckman Coulter) with the 28.8 PD-L1 antibody clone (Abcam). Cells 
were harvested from flasks using trypsin before being washed in phosphate buffered solution 
(PBS). 1x104 cells were suspended in 100μL of stain buffer (1% bovine serum albumin 
(BSA)/10% normal donkey serum (NDS) in PBS) containing PD-L1 (clone 28.8, Abcam) diluted 
1/100 for 30 minutes. The cells were then washed once with 0.5% BSA in PBS before 
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resuspending in stain buffer containing a secondary donkey anti-rabbit IgG antibody 
conjugated to Alexa Fluor® 488 (Abcam) diluted 1/500 for 30 minutes. The cells were once 
again washed once in 0.5% BSA in PBS before being resuspended in 100μL of stain buffer and 
analysed using a Gallios Flow Cytometer (Beckman Coulter). Fluorescence values obtained for 
each cell line were then compared to form a relative scale which was utilised to identify high, 
low and negative PD-L1 expressing cell lines which were subsequently used as controls. PD-
L1 expression levels for these control cell lines was then validated by immunocytochemistry 
to ensure expression readings were consistent between methods. 
2.3.3. WBC isolation from healthy volunteers 
Healthy donors signed consent forms, previously approved by the Human Research Ethics 
Committees at ECU (No.11543 and No.21261). The blood was drawn by phlebotomists into 
vacutainer tubes, containing EDTA anticoagulant (Becton-Dickinson). The first 6ml of blood 
was collected in SST tubes for serum collection, doubling as a discard tube to avoid epithelial 
contamination. 
Red blood cells (RBCs) were lysed using RBC lysing buffer (140mM NH4Cl + 17mM Tris in 
ddH2O, pH 7.65) at a 1:5 volume ratio with continuous gentle mixing for 10 minutes at room 
temperature. The lysed RBCs were removed by centrifugation at 300g for 5 minutes. 
Following this, the nucleated cell fraction was washed once with PBS and finally resuspend in 
PBS. Cells were then counted and diluted into 10,000 cell fractions. 
2.3.4. Spiking of cancer cell lines 
Cell lines were spiked into WBC fractions in order to mimic the cell population present after 
enrichment. For all immunocytochemistry spiking experiments involving WBCs, 
approximately 500 cells (from whichever cell line was required) were spiked into WBCs. 
Spiking carcinoma cells involved diluting to the appropriate concentration of cells and mixing 
the fraction with a 10,000 WBC fraction, obtained from a healthy volunteer as described in 
2.3.3. 
2.3.5. Carcinoma immunocytochemistry 
After collection, cells (from CTC isolation/ cell line spikes) were immediately fixed in 4% 
paraformaldehyde (PFA) for 10 minutes. After that, cells were cytospun (Cytospin™ 4, Thermo 
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Fisher Scientific) onto glass slides at 2000 rpm for 5 minutes at medium acceleration. Cells 
were then dried and stored in a desiccator at 4°C or progressed straight to staining. 
Cells were incubated in blocking buffer (10% NDS/ 10% Glycine/ 5% Human FcR block/ 3% 
BSA/ 0.2% TX in PBS) for 15 minutes before incubating in stain buffer (10% NDS/ 3% BSA/ 
0.2% TX in PBS) containing pan-cytokeratin clone CK3-6H5 conjugated to FITC (Miltenyi 
Biotech, Bergisch Gladbach, Germany), pan-cytokeratin clone C11 conjugated to Alexa Fluor® 
488 (Cell Signalling Technology, Danvers, United States of America), pan-cytokeratin clone 
AE1/AE3 conjugated to Alexa Fluor® 488 (ThermoFisher Scientific), EpCAM conjugated to FITC 
(clone VU-1D9, ThermoFisher Scientific), CD16 conjugated to phycoerythrin (PE) (clone 3G8, 
BioLegend), CD45 conjugated to PE (clone HI30, BD Biosciences) and vimentin conjugated to 
Alexa Fluor® 647 (clone v9, Abcam) (Table 2) for 1 hour. Following this incubation cells were 
washed three times for 5 minutes each in 1% BSA in PBS, washed in PBS for 5 minutes, dried 
and mounted with Fluoromount Gold plus DAPI (ThermoFisher Scientific). Mounted slides 
were stored at room temperature for 12-18 hours before imaging using an automated 
inverted Eclipse Ti-E Nikon® fluorescence microscope (detailed in section 2.3.8). After 
imaging, slides were immediately submerged in PBS to remove coverslips (~15 minutes). After 
coverslip removal slides were washed five times for 5 minutes each in PBS before incubating 
in 1mg/mL BH4 in PBS solution for 180 minutes in darkness, with the BH4 in PBS solution being 
replaced after 90 minutes. Slides were then washed six times for 5 minutes each in PBS before 
incubating in 100Mm tris solution for 1 hour. Slides were once again washed three times for 
5 minutes each in PBS before quenching endogenous peroxidase activity with 0.3% H2O2 for 
20 minutes. Slides were incubated in blocking buffer for 15 minutes before incubating in stain 
buffer containing PD-L1 (clone 28.8, Abcam) for 1 hour. Slides were then washed three times 
with 1% BSA in PBS for 5 minutes each and then incubated in stain buffer containing anti-
rabbit horseradish peroxidase (HRP) (1/200, Perkin Elmer) for 30 minutes. Slides were again 
washed three times with 1% BSA in PBS for 5 minutes each before incubating in TSA Plus 
working solution (TSA plus Cy5 kit, Perkin Elmer) for 5 minutes. Finally, slides were once again 
washed three times with 1% BSA in PBS for 5 minutes each, washed once in PBS for 5 minutes, 
dried and mounted with Fluoromount Gold plus DAPI (ThermoFisher Scientific). 
2.3.6. Patient recruitment 
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Patients beginning or receiving treatment for NSCLC were recruited by Professor Michael 
Millward (Sir Charles Gairdner Hospital, WA), Dr Samantha Bowyer (Sir Charles Gairdner 
Hospital, WA), Dr Adnan Khattak (Fiona Stanley Hospital, WA) and Dr Afaf Abed (Fiona Stanley 
Hospital, WA) prior to commencing therapy. Procedures were approved by Human Research 
Ethics Committees at Edith Cowan University (No. 18957) and Sir Charles Gairdner Hospital 
(No. 2013-246). Clinical data such as disease stage, prior therapy and forthcoming therapy 
was collected for all patients. At least 9mL of blood was collected from each patient into EDTA 
tubes, with one tube being used for each enrichment method where more than one method 
was employed. Samples were processed within 24 hours of blood collection. 
2.3.7. CTC enrichment and immunofluorescent staining 
Blood samples were enriched using the Parsortix system (Angle Plc) and in some cases, also 
processed with the ClearCell FX system (Biolidics Ltd, Singapore). Enriched cells were 
processed in accordance with the immunofluorescence staining methods described for NSCLC 
patients in section 2.3.5. Patient samples were periodically processed in tandem with high, 
medium and low PD-L1–expressing cell line controls to ensure consistent results. 
2.3.8. CTC identification and PD-L1 scoring 
Stained slides were scanned using an automated inverted Eclipse Ti-E Nikon® fluorescence 
microscope to visualise immunofluorescent staining and analysis was performed using the 
NIS-Elements High Content Analysis software, version 4.2.01. For the first scan, slides were 
scanned using; a DAPI filter with excitation and emission (Ex/Em) wavelengths of 395/460 nm 
with an exposure time of 300ms, a FITC only filter (Ex/Em = 470/535 nm) with an exposure 
time of 700ms and 2x2 binning, a TRITC filter (Ex/Em = 555/607 nm) with an exposure time of 
500ms and 2x2 binning, and a Cy5 filter (640/720 nm) with an exposure time of 1s and 2x2 
binning. For the second scan, slides were scanned using; a DAPI filter (Ex/Em =395/460 nm) 
with an exposure time of 300ms and a TRITC filter (Ex/Em = 555/607 nm) with an exposure 
time of 100ms. Look up tables, adjusted based on control slides, were used to remove 
background fluorescence and adjust displayed intensity appropriately. 
CTCs were identified among nucleated cell populations based on the size/morphology of cell, 
nuclear features and expression of cytokeratin, EpCAM and/or vimentin in the absence of 
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blood-lineage CD16 or CD45 expression. Detectable PD-L1 expression was scored as high or 
low based on positive controls. 
2.3.9. Tumour PD-L1 expression assessment 
Patient tumour biopsies were stained for PD-L1 at PathWest clinical laboratories using the 
22C3 antibody concentrate in Dako ASL48 Autostainers. Patient tumour PD-L1 score was 
determined by pathologists, considering external controls. Correlation between tumour 
tissue, scored as per pathologist estimation, and CTC PD-L1 positivity, scored based on 
positive controls, was assessed by plotting into a contingency table categorising each as either 
positive or negative.   
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3. CHAPTER 3: Results 
 
 
Section 3.1 includes sections from the following publication, of which I am an author, and 
responsible for the comparison of PD-L1 expression between tumour tissue and CTCs. 
Khattak, M. A., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M.H., Meniawy, T., 
Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., & Gray, E. (2019). PD-L1 
Expression on Circulating Tumour Cells May Be Predictive of Response to 
Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. Oncologist. 
doi:10.1634/theoncologist.2019-0557 
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3.1. Comparison of PD-L1 expression on CTCs assessed by flow cytometry to 
PD-L1 expression in matched tissue biopsies. 
As described in 1.6.2, a previous study in our laboratory assessed PD-L1 expression on CTCs 
from a cohort of metastatic melanoma patients prior to receiving pembrolizumab treatment 
(Khattak et al., 2019). CTCs were detected in 25/40 patients, with 14/25 CTC positive patients 
having ≥1 PD-L1 positive CTC. 
To compare PD-L1 expression between CTCs and matched tissue samples, a subgroup of 
patients was analysed. PD-L1 expression in the tumour was evaluated using the PD-L1 IHC 
22C3 pharmDx.  Only, 25 of the 40 patients assessed for CTCs by flow cytometry had tissue 
available for PD-L1 IHC. 14 cases had PD-L1 status data available for both the tumour and 
CTCs samples.  
Six patients were PD-L1+ in both tumour and CTCs, and all of them responded to therapy 
(Figure 15). Three patients were PD-L1+ in tumour (≤10% TPS) but not on CTCs, of which two 
of them responded to treatment. Two patients were PD-L1+ on CTCs but not in tissue, with 
one responding and the other not responding to treatment. Finally, three patients were PD-
L1- in both tissue and CTCs, and all failed to respond. 
  
Figure 15. Proportion of total CTCs (full bars) that express PD-L1 (red bars) at baseline in patients 
treated with pembrolizumab monotherapy. Patients were grouped based on therapeutic objective 
response. Tumour Proportion Scores indicating PD-L1 expression in the tumour tissue are indicated 
for each patient. (-) indicates not available tissues. 
Representative images of PD-L1 immunohistochemistry are shown in Figure 16. Only tumour 
cell PD-L1 is counted for assessment and tumour proportion score, with PD-L1 staining 
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depicted in brown and tumour cells being identified by pathologists. Of the three samples 
shown, one was concordant (MM130), and two were non-concordant with blood PD-L1 assessment. 
 
Figure 16. Photomicrographs showing immunohistochemical staining of PD-L1 with 22C3 antibody in 
three of the melanoma tissues evaluated. PD-L1 staining is evidenced by the presence of the brown 
chromogen, whereas blue is haematoxylin counterstain. Tumour proportion score (TPS) for each 
sample is indicated as well as the percentage of CTCs identified as PD-L1+. 
Interestingly, PD-L1 positivity in tumour tissue (≥1% TPS) was significantly associated with 
response to treatment (P=0.047) (Figure 17B). Furthermore, there were more responders in 
the PD-L1+ cohort irrespective of PD-L1 assessment through tissue or CTCs (P=0.014), 
suggesting both methods could be complimentary (Figure 17C).  
 
Figure 17. Comparison of response relative to PD-L1 expression on CTCs (A), tumour tissue (B) and 
either CTC or tumour tissue (C). Odds ratios (OR), 95% confidence intervals and P-values of two-sided 
Fisher’s exact tests are indicated for each graph.  
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3.2. Develop an immunocytochemistry assay to evaluate PD-L1 expression 
in melanoma CTCs 
3.2.1. Selecting a suitable anti-PD-L1 antibody 
There is a range of commercially available anti-PD-L1 antibodies to detect the presence of the 
PD-L1 protein in tumours (Hirsch et al., 2017). Of those, 130021 (R&D systems), 22C3 (DAKO) 
and 28.8 (DAKO) were chosen to test for their suitability to be incorporated into an 
immunocytochemistry panel for identification of CTCs (Table 3). First, each antibody was 
tested by flow cytometry, following the protocol detailed section 2.2.2 in the Materials and 
Methods.  
The melanoma cell line SKMEL28 was chosen to test the antibodies as it is known to 
constitutively express PD-L1, albeit at low levels (Johnson et al., 2016; Kim et al., 2018). 
Preliminary results showed that only the 28.8 antibody was effective at identifying PD-L1 
expression on SKMEL28 cells with a 1.9-fold shift in median intensity relative to the isotype-
matched control. Meanwhile the 130021 and 22C3 antibodies had only 1.1 and 1.2-fold shifts 
in median fluorescence intensity relative to their control samples respectively (Figure 18). 
Table 3. PD-L1 antibody clones assessed for suitability to include in immunocytochemistry panels. 
 
Figure 18. Histogram plots from flow cytometric analysis of PD-L1 expression on SKMEL28 cells using 
the 28.8 (A), 130021 (B) and 22C3 (C) antibodies. The 130021 antibody was conjugated to FITC, while 
22C3 and 28.8 antibodies were used as unconjugated primary antibodies with AF488 conjugated 
donkey anti-mouse and AF488 conjugated donkey anti-rabbit used as secondary antibodies 
Clone Company Uses References 
130021 R&D systems Used in previous CTC study (Khattak et al., 2019) 
22C3 DAKO FDA approved as companion 
diagnostic test for pembrolizumab 
treatment in NSCLC patients 
(Herbst et al., 2016; Reck 
et al., 2016) 
28.8 DAKO FDA approved as complementary 
diagnostic test for nivolumab 
treatment in NSCLC patients 
(Kazandjian et al., 2016) 
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respectively. All primary antibodies were diluted 1/100, both secondary antibodies were diluted 1/500. 
A FITC conjugated isotype matched antibody was used as the control for the 130021 antibody test. 
SKMEL28 cells stained with anti-mouse and anti-rabbit secondary antibodies conjugated to AF488 
(with no primary antibody) were used as controls for the 22C3 and 28.8 staining, respectively. 
To enhance PD-L1 expression, SKMEL28 cells were treated with different concentrations of 
interferon gamma (IFN-γ) over 24 hours.  Cells were then analysed by flow cytometry using 
the 28.8 PD-L1 clone (Figure 19a). The 5.8-fold shift in median fluorescence intensity relative 
to the non-induced cells, demonstrated that 100 ng/ml of IFN-γ significantly induced PD-L1 
expression and so this concentration was used for all subsequent IFN-γ inductions. However, 
neither the 130021 or 22C3 antibodies were able to clearly detect the increased PD-L1 
expression on SKMEL28 cells treated with 100 ng/ml of IFN-γ. The 130021 and 22C3 
antibodies had 1.2 and 1.7-fold shifts in median fluorescence intensity relative to the non-
induced cells, still reading low median fluorescence intensities (Figure 19b & c). This confirms 
that both the 130021 and 22C3 PD-L1 antibodies cannot be used to effectively measure PD-
L1 expression using flow cytometry. 
 
Figure 19. Histogram plots from flow cytometric analysis of PD-L1 expression on SKMEL28 cells after 
induction of PD-L1 expression with 100 ng/mL of IFN-γ, using the 28.8 (A), 130021 (B) and 22C3 (C) 
antibodies. The 130021 antibody was conjugated to FITC while 22C3 and 28.8 antibodies were used as 
unconjugated primary antibodies with AF488 conjugated donkey anti-mouse and AF488 conjugated 
donkey anti-rabbit secondary antibodies respectively. All primary antibodies were diluted 1/100, both 
secondary antibodies were diluted 1/500. A FITC isotype control was used as the control for the 130021 
antibody. SKMEL28 cells stained with secondary antibody but no primary antibody was used as the 
control for 22C3 and 28.8. 
As flow cytometry was only to be used to validate the antibodies and identify control cell lines 
and would not be used for the identification of PD-L1 on CTCs in patient samples, the three 
candidate PD-L1 antibodies were also tested by immunocytochemistry. SKMEL28 cells were 
seeded onto coverslips and allowed to grow for 48 hours before staining. Cells were then 
incubated in staining buffer (section 2.2.5) containing either the 28.8, 22C3 or 130021 
antibody clones. The coverslips were then washed three times for 5 minutes each in 1% BSA 
in PBS before incubating in staining buffer containing either AF488 conjugated donkey anti-
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rabbit secondary (28.8) AF488 conjugated donkey anti-mouse secondary (22C3) or no 
secondary antibody (130021). This was followed by washing three times for 5 minutes each 
in 1% BSA in PBS, washing once in PBS for 5 minutes, drying and mounting with Fluoromount 
Gold plus DAPI (ThermoFisher Scientific). Analysis of the immune stained cells demonstrated 
that only 28.8 was able to clearly detect PD-L1 expression, with the 130021 and 22C3 
antibodies only producing weak, inconsistent staining (Figure 20). This conclusion was 
consistent with the previous flow cytometry results (Figure 18). 
Next, SKMEL28 cells were seeded onto coverslips and grown for 24 hours before induction 
with 100 ng/mL of IFN-γ for 24 hours. Cells were then processed for PD-L1 
immunocytochemistry in the same manner as described above for non-induced cells. Results 
demonstrated that the SKMEL28 cells incubated with IFN-γ had a significantly increased signal 
from the 28.8 antibody, suggesting an increase in PD-L1 expression. However, while the PD-
L1 signal from these cells using the 130021 and 28.8 antibodies was higher than the signal 
when using the non-induced cells, it was drastically weaker than the signal from the 28.8 
antibody (Figure 21). Once again, these immunocytochemistry results are consistent with the 
previous flow cytometry results (Figure 19). From this point forward all PD-L1 analysis used 
the 28.8 antibody. 
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Figure 20. Photomicrographs depicting PD-L1 expression (green) on SKMEL28 cells grown on 
coverslips, using 28.8 (A), 130021 (B) and 22C3 (C) antibodies. Controls included a combined donkey 
anti-rabbit and donkey anti-mouse secondary antibodies but no primary antibody (D) and a FITC 
isotype control (E). The 130021 antibody was conjugated to FITC while 22C3 and 28.8 antibodies were 
used as unconjugated primary antibodies with AF488 conjugated donkey anti-mouse and AF488 
conjugated donkey anti-rabbit secondary antibodies respectively. All primary antibodies were diluted 
1/100, both secondary antibodies were diluted 1/500. Scale bar (top left) represents 50μm. 
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Figure 21. Photomicrographs depicting PD-L1 expression (green) on SKMEL28 cells grown on coverslips 
and induced with 100 ng/mL of IFN-γ, using 28.8 (A), 130021 (B) and 22C3 (C) antibodies. A control 
with combined donkey anti-rabbit and donkey anti-mouse secondary antibodies but no primary 
antibody (D) and a FITC isotype control (E). The 130021 antibody was conjugated to FITC while 22C3 
and 28.8 antibodies were used as unconjugated primary antibodies with AF488 conjugated donkey 
anti-mouse and AF488 conjugated donkey anti-rabbit secondary antibodies respectively. All primary 
antibodies were diluted 1/100, both secondary antibodies were diluted 1/500. Scale bar (top left) 
represents 50μm. 
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3.2.2. Identifying control cell lines for PD-L1 expression to use in the melanoma 
immunocytochemistry panel 
We aimed to identify melanoma cell lines that could serve as controls with high, low and 
negative PD-L1 expression. From previous results, SKMEL28 cells were found to constitutively 
express low levels of PD-L1 with a 1.9-fold shift in median fluorescence intensity relative to 
the primary control (Figure 18A), while SKMEL28 cells incubated with 100 ng/mL of IFN-γ over 
24 hours had a 5.8-fold shift in median fluorescence intensity relative to the non-induced cells 
(Figure 19A).  
Flow cytometry was used to assess several melanoma cell lines, demonstrating a range of PD-
L1 expression. (Figure 22). MP41 cells expressed negligible levels of PD-L1 with a 1.25-fold 
shift in median fluorescence intensity relative to the primary control (Figure 22b), and 
therefore chosen to be used as negative control.  
Overall, SKMEL28 induced with 100 ng/mL of IFN-γ for 24 hours was chosen as the high 
expression control, SKMEL28 without induction was chosen as the low expression control and 
MP41 was chosen as the negative control. 
 
Figure 22. Histogram plots from flow cytometric analysis of PD-L1 expression on A2058 cells (A), MP41 
cells (B), UACC62 cells (C), WM164 cells (D) and WM793 cells (E). The 28.8 antibody was diluted 1/100 
with AF488 conjugated donkey anti-rabbit secondary antibody diluted 1/500. Cells stained with 
secondary antibody but no primary antibody was used as the control. 
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3.2.3. Developing a melanoma immunocytochemistry panel 
A melanoma antibody cocktail consisting of S100, gp100 and MLANA was previously validated 
for detecting melanoma CTCs by Aya-Bonilla et al. (Aya-Bonilla et al., 2017). This melanoma 
marker cocktail was used to identify melanoma cells via two step staining using a donkey anti-
rabbit secondary antibody bound to Alexa Fluor® 488. As this cocktail was already validated, 
we added the 28.8 PD-L1 antibody conjugated to Alexa Fluor® 647, to the existing 
immunocytochemistry protocol. SKMEL28 cells, cytospun onto a glass slide, were stained with 
the 28.8-Alexa Fluor® 647 antibody to ensure appropriate results. As the Alexa Fluor® 647 PD-
L1 antibody is also rabbit derived, the two step staining used by Aya-Bonilla et al., could not 
be employed (Aya-Bonilla et al., 2017). To compensate, a third step was added, introducing 
the PD-L1 antibody only after the donkey anti-rabbit secondary and another wash step so as 
to avoid unintentional binding (Figure 23). However, false amplification of the PD-L1 signal 
was observed as the PD-L1 antibody bound to the remaining binding site on the bound donkey 
anti-rabbit secondary (Figure 24C). 
 
Figure 23. Workflow of immunocytochemistry staining for melanoma samples after cytospinning onto 
slides. Additional steps over standard staining (Aya-Bonilla et al., 2017) are indicated in orange boxes. 
* indicate steps were 10% normal rabbit serum was included. 
We modified the protocol by adding 10% normal rabbit serum to the PD-L1 staining buffer 
used in the third stain (Step 6, Figure 23). This reduced the unspecific binding of the PD-L1 
antibody to the donkey anti-rabbit conjugate, providing appropriate PD-L1 staining with 
similar intensity as was seen without the presence of the other antibodies, and maintaining a 
good staining of melanoma markers (Figure 24D). 
Permeabilisation 
and blocking
First stain:
Melanoma markers 
+ CD16 & CD45
Wash
Second stain:
Donkey anti-rabbit 
secondary antibody
Wash
Third stain*:
PD-L1
Wash & mount
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Figure 24. Photomicrographs depicting SKMEL28 staining with the 28.8 PD-L1 antibody alone and in combination with melanoma markers. AF647 PD-L1 alone 
with no melanoma marker staining (A), AF488 melanoma markers alone with no AF647 PD-L1 (B), AF488 melanoma markers in combination with AF647 PD-
L1 (C) and AF488 melanoma markers in combination with AF647 PD-L1 using normal rabbit serum to block non-specific binding (D). AF488 melanoma markers 
in green, AF647 PD-L1 in purple. The melanoma markers were used as unconjugated primary antibodies with AF488 donkey anti-rabbit secondary antibody. 
The melanoma marker S100 was diluted 1/500, the melanoma markers gp100 and MLANA were diluted 1/50 and the PD-L1 was diluted 1/100. Scale bar (top 
left) represents 20μm.
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Aya-Bonilla et al. used an anti-CD45 antibody to identify WBCs (Aya-Bonilla et al., 2017). 
However, we found that CD45 only provides staining of 60-80% of WBCs in Parsortix 
processed blood, as this process enriches in larger WBCs such as granulocytes which express 
low levels of CD45. Thus, we decided to bolster WBC identification with the addition of CD16. 
Both CD16 and CD45 are WBC markers, however, they can be differentially expressed on sub-
populations of cells. CD45 is not expressed on natural killer cells and is only weakly expressed 
on granulocytes, where CD16 expression on both granulocytes and natural killer cells is higher 
(Cherian et al., 2010). The addition of CD16 improved the WBC staining coverage from ~80% 
(CD45 alone) to 100% (CD45 plus CD16) (Figure 25). 
To test PD-L1 staining combined with the full immunocytochemistry panel for melanoma CTC 
detection, MP41, non-induced SKMEL28 and induced SKMEL28 cells were spiked into WBCs 
to provide control examples. Staining was carried our as described in section 2.2.5 of 
Materials and Methods which includes the key steps described above, addition of donkey 
serum with the anti-PD-L1 antibody and the use of CD45 and CD16 for WBC exclusion. The 
results demonstrated that the assay could effectively distinguish between high, low and 
negative PD-L1 expression whilst providing a good exclusion of WBCs (Figure 26). This staining 
protocol was then used to stain melanoma patient samples.
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Figure 25. Photomicrograph depicting WBCs stained with CD45 conjugated to PE (red) and CD16 conjugated to Cy5 (purple). Both the CD16 and CD45 
antibodies were diluted 1/50. Scale bar (top left) represents 20μm. Arrows identify cells with questionable/negative CD45 staining and strong CD16 staining. 
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Figure 26.  Photomicrographs depicting final immunocytochemistry staining of MP41 (A), SKMEL28 (B) and SKMEL28 induced with 100 ng/mL of IFN-γ (C) 
spiked into WBCs. Cells were cytospun and stained with AF488 melanoma markers in green, PE CD16 & CD45 in red, AF647 PD-L1 in purple. The melanoma 
markers were used as unconjugated primary antibodies with AF488 donkey anti-rabbit secondary antibody. The melanoma marker S100 was diluted 1/500, 
the melanoma markers gp100 and MLANA were diluted 1/50, the CD16 and CD45 antibodies were diluted 1/50 and the PD-L1 was diluted 1/100. Scale bar 
(top left) represents 20μm. White arrows identify cancer cells, red arrows identify WBCs.
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3.2.4. Melanoma patient samples 
Once the final methodology and control cell lines for assessment of the PD-L1 on melanoma 
cells by immunocytochemistry were developed, we proceed to analysed patient samples. As 
CTC analysis requires fresh blood samples recruitment and analysis were carried out from 
August 2019 to December 2019. Blood samples from 8 melanoma patients were collected, 
enriched, stained and evaluated for CTC number and PD-L1 expression. All samples were 
collected as baselines before commencing systemic therapy. CTCs were enriched using the 
Parsortix system and harvested cells were cytospun onto glass slides. The patient clinical 
characteristics are detailed below (Table 4).  
Table 4. Clinical characteristics of melanoma patients analysed 
Clinical characteristic n 
Patient median age* 77 (38-83) 8 
Gender  
Male 6 
Female 2 
Prior therapies†  
0 3 
1+ 5 
*At the time of blood sample collection. †Prior therapies were either chemotherapy (2 patients), 
targeted therapy (1 patient), immunotherapy (1 patient) or all of the above (one patient). 
In this pilot analysis, CTCs were detected in 3/8 (38%) of the patients, with the detected CTC 
number ranging from 1 to 9 (Figure 27). PD-L1 status of CTCs was evaluated in all 3 CTC 
positive samples, with 2/3 patients having at least one PD-L1 positive CTC (7 total). All 7 PD-
L1 positive CTCs demonstrated weak PD-L1 expression (Figure 28), comparable to signal 
observed in non-induced SKMEL28 cells. 
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Figure 27. Bar chart depicting the number and PD-L1 status of CTCs detected in the melanoma 
patient cohort.  
Of the 8 melanoma patient samples assessed, 7 samples exhibited a number of cells positive 
for the melanoma markers and for CD45/CD16, thus not deemed as CTCs. Some of these 
double positive cells also expressed PD-L1 (Figure 28).  
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Figure 28. Photomicrographs depicting representative cells isolated from melanoma patient blood 
samples. DP – Double positive for melanoma markers and CD16/CD45. AF488 melanoma markers in 
green, PE CD16 & CD45 in red, AF647 PD-L1 in purple. The melanoma markers were used as 
unconjugated primary antibodies with AF488 donkey anti-rabbit secondary antibody. The melanoma 
marker S100 was diluted 1/500, the melanoma markers gp100 and MLANA were diluted 1/50, the 
CD16 and CD45 antibodies were diluted 1/50 and the PD-L1 was diluted 1/100. Scale bar (top left) 
represents 10μm. 
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3.3. Develop an immunocytochemistry assay to evaluate PD-L1 expression 
in carcinoma CTCs 
3.3.1. Identifying control cell lines for PD-L1 expression to use in the carcinoma 
immunocytochemistry panel 
We next aimed to identify carcinoma cell lines that could serve as controls with high, low and 
negative PD-L1 expression. Flow cytometry was used to assess three available carcinoma cell 
lines for PD-L1 expression (Figure 29). MDA-MB231 and MCF7 are breast cancer cell lines, 
while LNCaP is a prostate cancer cell line. Lung cancer cell lines were not used to develop the 
staining panel as none were readily available, meanwhile; both breast and prostate cancer 
are epithelial carcinomas, making them appropriate for use as controls in the development 
of this protocol. The results demonstrated that MDA-MB-231 cells constitutively expressed 
high levels of PD-L1 with a 9.2-fold shift in median fluorescence intensity relative to the 
primary control (Figure 29B). MCF7 and LNCAP cells had no apparent shift in median 
fluorescence intensity relative to the primary control. 
MCF7 cells incubated with 100 ng/mL of IFN-γ for 24 hours had a 3.7-fold shift in median 
fluorescence intensity relative to the primary control (Figure 29A). Based on these flow 
cytometry results, MDA-MB-231 was chosen as the high expression control, MCF7 induced 
with 100 ng/mL of IFN-γ for 24 hours was chosen as the low expression control and MCF7 
without IFN-γ induction was chosen as the negative control. 
 
Figure 29.  Histogram plots from flow cytometric analysis of PD-L1 expression on MCF7 cells (A), MDA-
MB-231 cells (B) and LNCaP cells (C) using the 28.8 antibody diluted 1/100 with AF488 conjugated 
donkey anti-rabbit secondary antibody diluted 1/500. Cells stained with donkey anti-rabbit secondary 
antibody, but no primary antibody, were used as controls. MCF7 cells were analysed with and without 
induction of PD-L1 expression by incubation with IFN-γ for 24 hours. 
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3.3.2. Developing a carcinoma immunocytochemistry panel 
We sought to devise an immunocytochemistry staining panel for detection of PD-L1 
expression on carcinoma CTCs. Initially we tested a panel using three mixed pan-cytokeratins 
and anti-EpCAM antibodies conjugated to FITC to detect CTCs, anti-CD16 and anti-CD45 
conjugated to AF647 to exclude WBCs and the 28.8 antibody conjugated to AF555 for PD-L1 
assessment. This antibody combination was initially unsuccessful for carcinoma staining as 
the 28.8-AF555 antibody demonstrated weak staining on cells known to have high PD-L1 
expression, such as MDA-MB-231 cells. This weak signal required longer exposure time (1s) 
to detect, causing signal from the AF647 conjugated CD16 & CD45 to bleed-through into the 
PD-L1 detection channel, providing false positive staining (Figure 30, note the exact colour 
pattern of WBC in the PD-L1 and CD16/CD45 channels). Bleed-through fluorescence from the 
CD16/CD45-AF647 into the PD-L1 channel was evident as not all WBCs will express PD-L1 (Ilié 
et al., 2017), yet every cell positive for CD16/CD45 was also positive for PD-L1. Increasing the 
concentration of the PD-L1 did not sufficiently increase the strength of the fluorescent signal 
to resolve this issue (data not shown).  
 
Figure 30. Photomicrograph depicting MDA-MB-231 cells spiked into WBCs and stained with 
FITC/AF488 conjugated mixed pan-cytokeratins & EpCAM (green), AF555 PD-L1 (red) and AF647 CD16 
and AF647 CD45 (purple). The pan cytokeratin CK3-6H5 was diluted 1/50, the pan cytokeratin C11 was 
  
 78 
diluted 1/100, the pan cytokeratin AE1/AE3 was diluted 1/200, the CD16 and CD45 antibodies were 
diluted 1/50 and the PD-L1 was diluted 1/100. Scale bar (top left) represents 20μm. Arrows identify 
cells where CD16/CD45 staining is affecting PD-L1 staining, evidenced by the identical staining pattern. 
To increase the signal for PD-L1 detection, we next introduced a tyramide signal amplification 
(TSA) step. TSA is an enzyme-mediated detection technique utilising the catalytic activity of 
HRP to generate a high-density labelled target protein thereby providing an intensified 
staining signal (Litt and Bobrow, 2002). Validation of the TSA staining protocol was performed 
on MDA-MB-231 cells seeded onto coverslips and allowed to grow for 48 hours before 
staining. Cells were fixed in 4% PFA for 10 minutes and incubated in blocking buffer for 15 
minutes before incubating in stain buffer containing unconjugated 28.8 PD-L1 antibody 
diluted 1/100 for 1 hour. Cells were then washed three times for 5 minutes each in 1% BSA-
PBS before incubating in stain buffer containing anti-rabbit horseradish peroxidase diluted 
1/100 for 30 minutes. Slides were again washed three times with 1% BSA-PBS for 5 minutes 
each before incubating in TSA Plus working solution containing a Cy3 fluorophore for 5 
minutes. Following this incubation cells were washed three times for 5 minutes each in 1% 
BSA-PBS, washed in PBS for 5 minutes, dried and mounted with Fluoromount Gold plus DAPI. 
The initial concentrations of 1/100 for both the HRP and PD-L1 produced oversaturated 
photomicrographs (not shown).  This was rectified by adjusting the concentrations of the PD-
L1 and HRP to 1/400 and 1/200 respectively. The scanning settings were also adjusted to scan 
at 100ms without binning to provide optimal signal with minimal background (Figure 31).  
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Figure 31. Photomicrograph depicting Cy3 TSA PD-L1 staining (red) of MDA-MB-231 cells grown on 
coverslips (A) and a control without the PD-L1 antibody (B). The 28.8 PD-L1 antibody was used 
unconjugated, diluted 1/400, the horseradish peroxidase was diluted 1/200 and the TRITC channel was 
scanned without binning at 100ms exposure to detect the PD-L1 TSA. Scale bar (top left) represents 
50μm. 
To validate the PD-L1 TSA staining in combination with the full NSCLC CTC staining protocol, 
MDA-MB-231 cells were spiked into WBCs and cytospun onto a glass slide. The cells were 
processed and stained as per the carcinoma staining detailed in section 2.3.5 of the Materials 
and Methods, with a few exceptions. For this test the CD16 and CD45 antibodies were 
conjugated to AF647 and the PD-L1 TSA was performed in tandem with the other antibody 
incubations.  
Although the TSA successfully increased the intensity of the PD-L1, it also resulted in the TSA 
fluorescent signal bleeding-through into the FITC channel. The bleed into the FITC channel 
from the TSA affected the appearance and reliability of the cytokeratin/EpCAM staining which 
is critical for accurate CTC identification (Figure 32). 
To overcome this problem, we separated the identification of carcinoma cells from PD-L1 
detection by performing two rounds of staining on the same cells/slide. We utilised 
borohydride to quench the fluorescent signal after the first round of immunostaining. The 
borohydride quenching protocol was adapted from (Adams et al., 2016). who performed the 
same protocol with the only difference being a reduced incubation time in borohydride of 90 
minutes, compared to the 180 minutes used in our protocol. Their protocol demonstrated 
that a 90 minute incubation in borohydride reduced fluorescence by 99% (Adams et al., 2016). 
The inclusion of borohydride quenching in our new protocol would allow identification of 
CTCs and exclusion of WBCs in the first immunostaining, while the second stain would allow 
characterising PD-L1 expression.  
As PD-L1 was removed from the first stain rounds in this protocol, a channel became available 
for assessment for additional makers. Thus, vimentin could be added to potentially identify 
further CTCs. Vimentin is a structural protein expressed in mesenchymal cells and can be 
expressed on certain cancer cells, including CTCs (Lindsay et al., 2016). Vimentin expression 
in epithelial cancer cells has been demonstrated to be involved in epithelial to mesenchymal 
transition of these cells and so can be used as a marker to detect more mesenchymal cancer 
cells that may have lost epithelial markers (Liu et al., 2015). Identification of these cells that 
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have undergone epithelial to mesenchymal transition (EMT) is of particular value as they have 
higher migration and invasion potential when compared to epithelial CTCs. The effects of EMT 
also demonstrate increased resistance to chemotherapy and immune escape capabilities 
beyond their epithelial counterparts (Satelli et al., 2017). 
The resulting final protocol is detailed in section 2.3.5 of the Materials and Methods. Final 
validation of this method was performed by spiking the control cell lines (MCF7 – negative for 
PD-L1 expression, MCF7 induced with IFN-γ – low PD-L1 expression & MDA-MB-231 – high 
PD-L1 expression) into WBCs and performing the entire staining protocol (Figure 33). As 
expected, MCF7 cells demonstrated strong CK/EpCAM staining and no detectable vimentin 
staining while MDA-MB-231 cells demonstrated weak CK/EpCAM staining and strong 
vimentin staining. PD-L1 was expressed at low levels in the IFN-γ induced MCF7 cells and 
strongly expressed in the MDA-MB-231 cells. All MCF7 cells, both IFN-γ induced and not, and 
all MDA-MB-231 cells were negative for the WBC markers CD16 and CD45.
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Figure 32. Photomicrograph depicting MDA-MB-231 cells spiked into WBCs and stained with Cy3 TSA PD-L1 (red), AF647 CD16 and AF647 CD45 (purple) plus 
FITC/AF488 conjugated mixed pan-cytokeratins & EpCAM (green) (A) and a control slide with no CK/EpCAM staining (B). The pan cytokeratin CK3-6H5 was 
diluted 1/50, the pan cytokeratin C11 was diluted 1/100, the pan cytokeratin AE1/AE3 was diluted 1/200, the CD16 and CD45 antibodies were diluted 1/50 
and the PD-L1 antibody was diluted 1/400. Scale bar (top left) represents 20μm. Arrows identify cells where PD-L1 staining is affecting CK/EpCAM staining, 
evidenced by the identical staining pattern despite the absence of CK/EpCAM staining. 
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Figure 33. Photomicrographs depicting MCF7 cells (A), IFN-γ induced MCF7 cells (B) and MDA-MB-231 
cells (C) immune staining with the final carcinoma panel. Cells were stained with FITC/AF488 mixed 
pan-cytokeratins and EpCAM (green), PE CD16 and CD45 (red), AF647 vimentin (purple) and Cy3 TSA 
PD-L1 (yellow). The pan cytokeratin CK3-6H5 was diluted 1/50, the pan cytokeratin C11 was diluted 
1/100, the pan cytokeratin AE1/AE3 was diluted 1/200, the CD16 and CD45 antibodies were diluted 
1/50 and the vimentin antibody was diluted 1/100. The PD-L1 stain was performed after borohydride 
quenching and the PD-L1 antibody was diluted 1/400. Scale bar (top left) represents 10μm. 
3.3.3. NSCLC patient samples 
Once the methods for the carcinoma PD-L1 immunocytochemistry panel were developed, 
NSCLC patient samples were analysed from May 2019 to December 2019. The patient clinical 
characteristics are detailed below (Table 5). Blood samples from 14 stage IV NSCLC patients 
were collected, enriched, stained and evaluated for CTC number and PD-L1 expression. All 14 
blood samples were collected before commencing systemic therapy and processed by the 
Parsortix system. Seven of the 14 patients had a second sample processed by the ClearCell FX 
system for comparison.  
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Table 5. Clinical characteristics of NSCLC patients analysed. 
Clinical characteristic n 
Patient median age* 67 (54-87) 14 
Gender  
Male 9 
Female 5 
Histopathology  
Adenocarcinoma 5 
Squamous-cell carcinoma 9 
Stage IV subclass*  
M1a 4 
M1b 4 
M1c 6 
Prior therapies  
0 9 
1+ 5 
Median days between biopsy and blood 65 (30-565) 
All prior therapies were chemotherapy cycles 
 *At the time of blood sample collection. 
CTCs were detected in 5/14 (36%) of the patients analysed. In the 5 patients with detectable 
CTCs, the CTC number ranged from 1 to 214 (median number of CTCs = 8) (Figure 34). CTCs 
were detected in 4/14 total patient samples processed through the Parsortix system. For the 
7 patients with samples processed through both enrichment systems; CTCs were detected in 
3/7 (43%) patient samples after enrichment with the Parsortix system, while CTCs were 
detected in 2/7 (29%) patient samples after enrichment with the ClearCell FX system. Only 
one patient had CTCs detected after enrichment through both systems (L909), and it was the 
case with the largest number of CTCs identified. Thus, the lack of concordance between the 
systems might be the result of heterogeneous distribution of low number of CTCs in the 
collection tubes. 
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Figure 34. Bar chart indicating CTC detection in NSCLC patients. CTCs were quantified after enrichment 
with the Parsortix systems (red bars). *These patients only had a sample processed through the 
Parsortix system (Red bars). 
The identified CTCs were classified into three categories, cytokeratin/EpCAM positive - 
classical CTCs, vimentin positive - epithelial to mesenchymal transition (EMT) CTCs and 
cytokeratin/EpCAM & vimentin positive - hybrid CTCs. Classical CTCs were detected in 2/14 
(14%) patients, EMT CTCs were detected in 4/14 (29%) patients and hybrid CTCs were 
detected in one patient. The number of classical CTCs detected ranged from 1 to 3 and the 
number of EMT CTCs ranged from 4 to 126 (median number of EMT CTCs 11.5).  Six Hybrid 
CTCs were detected in the patient with the largest number of CTCs (L909) (Figure 35), with all 
of them detected in the sample enriched using the ClearCell FX system.   
 
Figure 35. Stacked bar chart depicting the breakdown of CTC sub-populations detected in NSCLC 
patients. Samples processed through Parsortix – P, Samples processed through ClearCell FX – CC. 
Significant phenotypic and morphological heterogeneity was observed in CTC detected in 
patient blood samples (Figure 36). CTCs were classified as DAPI+, CD16/CD45-, 
Cytoketatin/EpCAM+ (classical CTCs) and/or Vimentin+ (EMT CTCs) (Figure 36).  
Of the 14 melanoma patient samples assessed, 10 samples exhibited a number of cells 
positive for CK/EpCAM and for CD45/CD16, thus not deemed as CTCs. Some of these double 
positive cells also expressed PD-L1 (Figure 28).  
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Figure 36. Photomicrographs depicting representative cells isolated from NSCLC patient blood samples 
stained with FITC/AF488 mixed pan-cytokeratins and EpCAM (green), PE CD16 and CD45 (red), AF647 
vimentin (purple) and Cy3 TSA PD-L1 (yellow). The pan cytokeratin CK3-6H5 was diluted 1/50, the pan 
cytokeratin C11 was diluted 1/100, the pan cytokeratin AE1/AE3 was diluted 1/200, the CD16 and 
CD45 antibodies were diluted 1/50 and the vimentin antibody was diluted 1/100. The PD-L1 stain was 
performed after borohydride quenching and the PD-L1 antibody was diluted 1/100. DP – double 
positive for cytokeratin/EpCAM and CD16/CD45. *Merge images do not include PD-L1 
photomicrographs. Scale bar (top left) represents 10μm. 
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PD-L1 status of CTCs was evaluated in all 5 CTC positive samples, with 4/5 patients having ≥1 
PD-L1 positive CTC. The number of PD-L1 positive CTCs ranged from 1-167 (median PD-L1 
positive CTCs 3.5) and the fraction of PD-L1 positive CTCs ranged from 0 to 100% of the total 
number of detectable CTCs (Figure 37). PD-L1 positive CTCs were further split into PD-L1 weak 
and PD-L1 strong CTCs based on controls, with the majority (117/175 or 67%) being strongly 
PD-L1 positive comparable to the signal in MDA-MB-231 cells. 
All 14 patients had tumour tissue evaluated for PD-L1 status using DAKO autostainers and the 
22C3 PD-L1 clone. PD-L1 status of tumour tissue ranged from 0 to 95% (median tissue PD-L1 
status 75%) as determined by pathologists. Tissue PD-L1 status was compared to CTC number 
and PD-L1 status for the 5 CTC positive patients. No clear correlation between PD-L1 positivity 
in CTCs and tumour tissue was observed (Figure 37). For example, L882 had a tissue PD-L1 
score of 95% while only 40% of CTCs were positive for PD-L1. On the other extreme L909 was 
PD-L1 negative on the tumour but 86% of CTCs evaluated were positive for PD-L1. 
 
Figure 37. Bar chart comparing PD-L1 status of tissue to number and PD-L1 status of CTCs. Only 
including patients with detectable CTCs. Tissue PD-L1 percentage is depicted in beige, CTC number is 
depicted in blue split into PD-L1 positive CTCs (dark blue) and PD-L1 negative CTCs (light blue). Samples 
processed through Parsortix – P, Samples processed through ClearCell FX – CC. * These patients 
received first-line chemotherapy between tissue and blood collection. 
Importantly, there were substantial differences between the dates of tissue biopsy and blood 
sample collection for all 14 cases, ranging from 30-365 (median delay 65 days. The delays are 
shown in Figure 37 with two patients receiving chemotherapy as first-line treatment. This may 
explain the discordances observed on PD-L1 expression.  
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4. CHAPTER 4: Discussion 
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4.1. CTC detection in melanoma patients 
PD-L1 expression in tissue has been linked to anti-PD-1 therapy outcomes in melanoma 
patients by previous studies. However, this association has not been statistically significant or 
clinically applicable (Daud et al., 2016; Kaunitz et al., 2017; Topalian et al., 2012). PD-L1 
expression in tissue has the potential to be a predictive marker, though, inter- and intra-
tumour heterogeneity pose a problem if only a single tumour is biopsied for tissue PD-L1 
analysis. Meanwhile, analysis of PD-L1 expression on CTCs has been heralded as a potential 
alternative as CTCs could be representative of all tumours within the body, accounting for 
heterogeneity. However, PD-L1 expression on CTCs has not been sufficiently studied to 
provide conclusive evidence of clinical utility. From our results, two clear limiting factors for 
evaluation of PD-L1 expression on CTCs are (i) the low number of detectable CTCs and (ii) the 
low CTC detection rate in melanoma patients requiring systemic treatment. 
Studies assessing CTC detection in melanoma patients by immunocytochemistry have 
produced wildly inconsistent results, with detection rates ranging from 23 – 100% (Freeman 
et al., 2012; Joshi et al., 2014; Khoja et al., 2013; Po et al., 2019; Rao et al., 2011). The 
detection rate of 38% in this study is therefore still comparable to that of other studies. 
However, an interesting comparison can be made to a publication by Joshi et al.  where they 
found CTCs in 100% of patient samples (Joshi et al., 2014). Like in our study, Joshi et al. used 
MLANA and S100 (albeit different antibody clones) to identify melanoma CTCs and used CD45 
as a negative marker for WBCs. The significant differences between the studies are the 
enrichment methods, where this study used the Parsortix system and they used CD45 
negative selection. Notably, we added anti-gp100 and anti-CD16 antibodies to the 
immunocytochemistry panel. The addition of CD16 allows exclusion of neutrophils and 
monocytes which stain low for CD45, improving WBC coverage. As a result, we detected 
double positive cells at a much higher frequency than CTCs. We found double positive cells 
(i.e. positive for melanoma and WBC markers) in 7/8 patient samples analysed. Joshi et al. 
and other studies mention detecting double positive cells expressing melanoma and WBC 
markers, but do not provide any further information, making comparison between studies 
difficult. The identity and role of these double positive cells are currently unknown, with them 
potentially being tumour-leukocyte hybrids, the result of staining artifacts or something else 
entirely. 
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To date, there have only been two other studies assessing PD-L1 expression on melanoma 
CTCs. In the earliest study by Khattak et al. we detected PD-L1 expression on 16/25 patients 
with the PD-L1 positive fraction of CTCs ranging from 1-89%. In this study, we found that CTC 
PD-L1 status was superior to other baseline clinical parameters associated with response and 
prognosis, including lactate dehydrogenase, disease stage and ECOG performance status 
(Khattak et al., 2019). However, CTCs analysed by immunocytochemistry can be recovered 
and used for some downstream analysis such as assessing copy number alterations to confirm 
that they are CTCs (Beasley et al., 2018; Carter et al., 2017). On the contrary, cells analysed 
by flow cytometry are lost, allowing no further analysis to be performed. It is this reasoning 
that led to the development of the immunocytochemistry panel for PD-L1 assessment on 
melanoma CTCs for our second study. For this second study, we used the Parsortix system to 
enrich for CTCs and developed a multimarker immunocytochemistry panel to detect them. 
From this cohort, we detected PD-L1 positive CTCs in 2 of the only 3 CTC positive patients. 
The results highlight that PD-L1 expression can be easily assessed, but the low detection rate 
is problematic.  
As covered in section 3.2.1, the 130021 PD-L1 antibody was used in our previous study 
(Khattak et al., 2019), and assessed for inclusion in this second study. Interestingly, we found 
that 130021 could not effectively measure PD-L1 expression on cell lines when processed by 
either flow cytometry or immunocytochemistry. These findings contradict the results from 
the previous study, which demonstrated detectable PD-L1 expression on CTCs from 
melanoma patients (Khattak et al., 2019). This may have been caused by various factors, the 
most likely of which I believe to be different presentation of the PD-L1 protein between fresh 
CTCs and the cell lines. The epitope identified by the 130021 antibody may be more readily 
accessible on CTCs when compared to cell lines or to tissue, thus explaining the difference in 
antibody effectiveness. This could not be assessed for the second study as the antibody panel 
needed to be validated using cell lines before being used on patient samples. 
Po et al. published the only other study to have assessed PD-L1 expression on melanoma 
CTCs, they used a multimarker immunocytochemistry panel to detect melanoma CTCs and 
assess PD-L1 expression. Po et al. detected PD-L1 expressing CTCs in 38% of CTC positive 
patients, a lower fraction compared to both our flow cytometry (64%) and 
immunocytochemistry studies (66%) (Khattak et al., 2019; Po et al., 2019). However, the 
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limited cohort sizes of these immunocytochemistry studies do not allow for statistically 
significant analysis to be performed. With only one of these three studies reporting any 
predictive and prognostic data, it is not yet possible to determine if PD-L1 expression on CTCs 
may have the potential to be either a predictive or a prognostic marker. 
Only one study has compared PD-L1 expression on CTCs to that in matched tissue samples 
used flow cytometry for CTC analysis (Khattak et al., 2019). Patients with PD-L1 positivity on 
CTCs or tumour tissue had a high probability of response suggesting both methods could be 
complimentary, with concordant results in tissue and CTCs predicting response to treatment 
with 100% accuracy (Khattak et al., 2019). Intra-tumour heterogeneity could impact the 
correlation between CTC PD-L1 expression and tissue PD-L1 expression, due to the potential 
for different sections of tissue to produce significantly different results (Madore et al., 2015). 
This is compounded by inter-tumour heterogeneity as the PD-L1 status of different tumours 
within a single patient may be completely different. 
 
4.2. CTC detection in NSCLC patients 
The average CTC detection rate in patients with metastatic NSCLC was 76%, based on the 9 
recent publications assessing PD-L1 expression on CTCs detailed in our review (Section 1.6.1) 
(Adams et al., 2017; Boffa et al., 2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et al., 2017; 
Kallergi et al., 2018; Kulasinghe et al., 2019; Nicolazzo et al., 2016; Wang et al., 2019). In 
comparison, the detection rate of CTCs in our study was 36%, much lower than that seen 
these recent reports. However, a combination of different CTC enrichment methods, staining 
and classification of CTCs could explain this discordance.  
Of the 9 recently published studies, 8 used label-free detection methods, with 6 different 
enrichment techniques being employed (Adams et al., 2017; Boffa et al., 2017; Dhar et al., 
2018; Guibert et al., 2018; Ilié et al., 2017; Kallergi et al., 2018; Kulasinghe et al., 2019; Wang 
et al., 2019). Though this would seem to be more comparable to the data from this study, the 
differences in CTC detection between the two label-free detection methods utilised in this 
study suggest that there can be significant differences in the cell populations produced by 
each. 
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Of the 9 recent publications assessing PD-L1 on NSCLC CTCs, 6 used CD45 as a negative marker 
for CTCs. However, none of the publications elected to use more than one negative marker 
beyond CD45 (Adams et al., 2017; Boffa et al., 2017; Dhar et al., 2018; Guibert et al., 2018; 
Ilié et al., 2017; Kallergi et al., 2018; Kulasinghe et al., 2019; Nicolazzo et al., 2016; Wang et 
al., 2019). This study found that the use of CD16 significantly reduced the number of false 
positive CTCs detected by immunocytochemistry, by correctly identifying them as double 
positive cells (DAPI+, CK/EpCAM+ & CD16/CD45+). We detected double positive cells in 10/14 
(71%) NSCLC patients. As the double positive cells were generally more abundant than CTCs, 
these numbers more closely matching the average rate of CTC detection seen in published 
studies. 
Use of the EMT marker vimentin to identify CTCs has the caveat of needing to exclude 
vimentin expressing WBCs. However, we believe that including cell features as well as a 
combination of negative markers (CD16/CD45) removes the background of vimentin 
expressing WBCs. We found that including vimentin significantly increased the detection of 
CTCs in our patient cohort, none of the 9 previously mentioned recent studies utilised EMT 
markers (Adams et al., 2017; Boffa et al., 2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et 
al., 2017; Kallergi et al., 2018; Kulasinghe et al., 2019; Nicolazzo et al., 2016; Wang et al., 
2019). 
Another difference to consider between our study and the 9 recent NSCLC CTC studies is the 
type and number of previous treatments. In our study, 5 of the 14 patients had received 
chemotherapy. However, our cohort size was too small to determine what affect prior 
chemotherapy treatments had on CTC number or PD-L1 expression in the second line 
patients. Of the 9 previously mentioned studies, 4 had treatment naïve patient cohorts, 1 had 
only chemotherapy relapse patients and the remaining 4 did not specify if patients had prior 
treatments or what prior treatments they may have received. Prior treatments may have 
differing effects on the tumours present in a patient depending on both how recent it was 
and the treatment type. Any impact that a treatment has on the tumour will likely affect the 
type and number of CTCs present in the blood, though the degree to which treatments affect 
CTC production are relatively unknown. 
Our study demonstrated that CTC PD-L1 expression was not concordant with tissue PD-L1 
expression. Recent publications have had mixed results when assessing the correlation 
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between the expression of PD-L1 on CTCs and its expression in tumour tissue (Adams et al., 
2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et al., 2017). In addition to our study, two of 
the four published studies had limited size patient cohorts, thus preventing statistical analysis 
(Adams et al., 2017; Dhar et al., 2018). However, the two studies with large patient cohorts 
reported contrasting results, with Ilié et al. (n=106) suggesting that the two were 93% 
concordant while Guibert et al. (n=96) found no statistically significant correlation between 
the two (Guibert et al., 2018; Ilié et al., 2017). The contrasting results are likely due to a variety 
of factors that differ from study to study. Labelled and label-free CTC enrichment techniques 
are known to isolate different numbers and populations of CTCs from similar patient cohorts 
(Adams et al., 2017; Boffa et al., 2017; Dhar et al., 2018; Guibert et al., 2018; Ilié et al., 2017; 
Kallergi et al., 2018; Kulasinghe et al., 2019; Nicolazzo et al., 2016; Wang et al., 2019). This 
study even demonstrated differences in CTC detection between two label-free enrichment 
techniques, adding another cofounding factor for concordance between CTC and tissue PD-
L1. 
Another reason for the concordance, or lack thereof, between CTCs and tissue may be the 
delay between biopsy and blood sample collection. Our study had significant differences in 
the delay between tissue biopsy dates and blood sample collection, ranging from 30-365 
(median delay 65 days). Of the 4 studies correlating CTC PD-L1 expression with tissue PD-L1 
expression, 3 do not state the delay between sample collections (Adams et al., 2017; Dhar et 
al., 2018; Guibert et al., 2018). Meanwhile Ilié et al. collected both samples on the same day 
and found that they had statistically significant concordance between PD-L1 expression on 
the samples (Ilié et al., 2017). It is theorised that CTCs may utilise the same tumour escape 
mechanisms as the tumour from which they derive. However, the longer the delay between 
tissue and blood samples, the more opportunity the tumour has to change and express 
different surface markers. 
Inter- and intra-tumour heterogeneity may also have a significant impact on correlation. It is 
believed that CTCs may arise from any tumour, yet only a single tumour is biopsied for tissue 
PD-L1 analysis. Intra-tumour heterogeneity could impact the correlation between CTC PD-L1 
expression and that of tissue as the section of tissue being assessed can significantly affect 
the results (Ilie et al., 2016). This is compounded by inter-tumour heterogeneity as the PD-L1 
status of different tumours within a single patient may be completely different. 
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Finally, the PD-L1 antibodies used to characterise the PD-L1 expression on CTCs and in tissue 
samples are likely to affect correlation between the two. Though efforts were made to ensure 
the same clone was used for both applications, this study used the 28.8 clone (DAKO) for CTCs 
and the 22C3 clone (DAKO) for tissue samples. The subtle differences in binding domains of 
each antibody is known to produce different staining patterns in tissue samples (Hirsch et al., 
2017; Tsao et al., 2018). This study also observed significant differences in the pattern and 
intensity of ICC PD-L1 staining between three commonly used clones. The potential 
differences in PD-L1 characterisation from using different clones are likely to be compounded 
by using different clones for each application. 
However, as there have been a limited number of studies, the degree to which each of the 
previously mentioned caveats affects correlation between PD-L1 expression on CTCs and in 
tissue is still unknown. 
 
4.3. Limitations of the study 
The primary limitation of this study was realised in the low number of patients that could be 
analysed during the study period, compound by the number and frequency of CTCs recovered 
in the patients analysed. Neither the ClearCell FX or the Parsortix systems are able to 
successfully isolate CTCs from all melanoma and NSCLC patient blood samples processed. 
However, whether this issue is biological or technical remains unclear as few studies report 
CTC detection rates of 100% (Boffa et al., 2017; Joshi et al., 2014; Wang et al., 2019).  
A secondary limitation was the varied timeframe between the tumour biopsy and blood 
collection for the analysis of CTC PD-L1 expression. This delay varied significantly between 
patient samples, with the effect of this delay on the expression of PD-L1 being relatively 
unknown. 
The final limitation is that the length of this study, within the constraints of a master’s degree, 
did not provide enough time to follow up disease outcome in sufficient patients to assess if 
PD-L1 expression on CTCs is predictive of response to anti-PD-1 therapy independently of the 
correlation with tumour PD-L1 status, as carried out in Khattak et al. This time constraint also 
affected the capacity to evaluate progression free survival and overall survival on these 
cohorts. 
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4.4. Future directions 
Building upon the methodologies developed and preliminary evaluated in this study, future 
research should assess PD-L1 expression on CTCs in larger cohort of patients and evaluate if 
it can predict response to treatment and/or survival. In addition, the correlation between PD-
L1 expression on CTCs and in tumour tissue will need to be more consistent with for several 
factors such as number of prior treatments, time of sample collection and anti-PD-L1 antibody 
utilised. Further studies will also be needed to determine if PD-L1 expression on CTCs can be 
a predictive or prognostic marker. 
This project has provided staining protocols to act as a basis for further studies to assess PD-
L1 on CTCs from melanoma and carcinoma patients. The use of borohydride quenching in the 
carcinoma staining panel may allow for, further improvement to these protocols through the 
addition of markers to improve both positive and negative CTC identification, such as N-
cadherin and CD66b (Alvarez Cubero et al., 2017). 
It will be important for future studies to assess PD-L1 expression on CTCs as a predictive or 
prognostic marker for combinations of anti-PD-1 therapy and chemotherapy. Combination of 
pembrolizumab with chemotherapy has been approved for the treatment of NSCLC and is 
seen to be highly effective (Langer et al., 2016; Paz-Ares et al., 2018; Sheela et al., 2018). 
However, like pembrolizumab monotherapy, this combination lacks a definitive predictor of 
response. 
4.5. Conclusions 
This project delivered multimarker immunocytochemistry assays to evaluate PD-L1 
expression on CTCs from both melanoma and NSCLC patients, including the establishment of 
negative, low and high positive controls. Analysis of blood samples from two small cohorts 
show the presence of CTCs in a low proportion of patients; in 3 out of 8 melanoma and 5 out 
of 14 NSCLC patients. However, PD-L1 was detected in large proportion of the CTC positive 
cases; in 2 out of 3 melanoma and 4 out of 5 NSCLC patients. We did not observe a good 
correlation between PD-L1 expression on CTCs and that in matched tumour tissue samples. 
However, there were a variety of potential confounding factors such as small sample size, 
antibody clone and time differences between tumour and blood collections.   
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Addition of the EMT marker vimentin significantly improved detection of NSCLC CTCs, while 
the addition of CD16 improved exclusion of WBCs for all patient samples, overall increasing 
the sensitivity and specificity of the assay. The use of TSA amplification greatly improved 
quantification of PD-L1 expression, allowing for the reliable detection of weak expression. 
Finally, the introduction of multiple rounds of staining through the application of borohydride 
quenching provides a means to expand the immunocytochemistry panel, beyond the protocol 
described herein. 
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